News Releases

Date Title
11/12/19
Summary ToggleSunesis Pharmaceuticals Reports Third Quarter 2019 Financial Results and Recent Highlights Phase 1b/2 Trial of Vecabrutinib in 400 mg Cohort; Clinical Update at Upcoming ASH Annual Meeting  Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals , Inc. (Nasdaq: SNSS) today reported financial
11/08/19
Summary ToggleSunesis Pharmaceuticals to Present at 28th Annual Credit Suisse Healthcare Conference SOUTH SAN FRANCISCO, Calif. , Nov. 08, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Willie Quinn , Chief Financial Officer and Senior Vice President, Finance and Corporate Development of Sunesis, will present at the 28 th Annual Credit Suisse Healthcare
11/06/19
Summary ToggleSunesis Pharmaceuticals Announces Presentation at 61st American Society of Hematology Annual Meeting SOUTH SAN FRANCISCO, Calif. , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced a poster presentation at the 61 st American Society of Hematology (ASH) Annual Meeting to be held December 7-10, 2019 in Orlando, Florida .
10/29/19
Summary ToggleSunesis Pharmaceuticals to Host Conference Call on November 12th to Discuss Third Quarter 2019 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif. , Oct. 29, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Tuesday, November 12 th , 2019 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the third quarter ended
10/16/19
Summary ToggleSunesis Pharmaceuticals Announces Presentation of SNS-510 Preclinical Data at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics SOUTH SAN FRANCISCO, Calif. , Oct. 16, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced a poster presentation at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held October 26-30, 2019 in Boston, Massachusetts
09/19/19
Summary ToggleSunesis Pharmaceuticals Appoints Dr. Nicole Onetto to the Board of Directors SOUTH SAN FRANCISCO, Calif. , Sept. 19, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Dr. Nicole Onetto , M.D. has been appointed to the Sunesis Board of Directors. Dr. Onetto brings over 20 years of oncology drug development experience to the Board. “Dr.
08/28/19
Summary ToggleSunesis Pharmaceuticals to Present at the Wells Fargo Healthcare Conference SOUTH SAN FRANCISCO, Calif. , Aug. 28, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Willie Quinn , Chief Financial Officer and Senior Vice President of Finance and Corporate Development, will present at the Wells Fargo Healthcare Conference on
08/07/19
Summary ToggleSunesis Pharmaceuticals Reports Second Quarter 2019 Financial Results and Recent Highlights Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif. , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the quarter ended June 30, 2019 . Loss from operations for the three and six months ended
07/31/19
Summary ToggleSunesis Pharmaceuticals to Host Conference Call on August 7th to Discuss Second Quarter 2019 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif. , July 31, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Wednesday, August 7 th , 2019 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the second quarter ended
07/11/19
Summary ToggleSunesis Announces Pricing of $25 Million Offering of Securities SOUTH SAN FRANCISCO, Calif. , July 10, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced the pricing of underwritten public offerings of (i) 33,333,667 shares of its common stock and (ii) 8,333 shares of its non-voting Series F Convertible Preferred Stock
07/10/19
Summary ToggleSunesis Announces Proposed Public Offering of Common Stock and Preferred Stock SOUTH SAN FRANCISCO, Calif. , July 10, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and Series F Convertible Preferred Stock in underwritten public
07/08/19
Summary ToggleSunesis Pharmaceuticals Announces Executive Promotions and Provides Clinical Update 300 mg Cohort of Phase 1b/2 Trial of Vecabrutinib now Enrolling SOUTH SAN FRANCISCO, Calif. , July 08, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the promotion of Judy Fox , Ph.D. from Chief Scientific Officer, Senior Vice President to Chief Scientific
06/15/19
Summary ToggleSunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at EHA Annual Meeting SOUTH SAN FRANCISCO, Calif. , June 15, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the presentation of results from the Company’s Phase 1b/2 clinical trial of its non-covalent BTK inhibitor vecabrutinib in adults with relapsed/refractory chronic lymphocytic
05/08/19
Summary ToggleSunesis Pharmaceuticals Reports First Quarter 2019 Financial Results and Recent Highlights Phase 1b/2 Trial of Vecabrutinib Advances into 200 mg Cohort Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif. , May 08, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the first quarter ended March
05/01/19
Summary ToggleSunesis Pharmaceuticals to Host Conference Call on May 8th to Discuss First Quarter 2019 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif. , May 01, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Wednesday, May 8 th , 2019 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the first quarter ended
04/29/19
Summary ToggleSunesis Pharmaceuticals Announces Refinancing of Existing Loan with $5.5 Million Loan from Silicon Valley Bank SOUTH SAN FRANCISCO, Calif. , April 29, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it has entered into a $5.5 million loan agreement with Silicon Valley Bank . The new agreement allows the company to retire its existing loan and defer any principal
04/03/19
Summary ToggleSunesis Pharmaceuticals to Present at 18th Annual Needham & Company Healthcare Conference SOUTH SAN FRANCISCO, Calif. , April 03, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Willie Quinn , Chief Financial Officer and Senior Vice President, Finance and Corporate Development of Sunesis, will present at the Needham & Company 18 th Annual
03/07/19
Summary ToggleSunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif. , March 07, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the fourth quarter and year ended December 31, 2018 .
03/04/19
Summary ToggleSunesis Pharmaceuticals to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif. , March 04, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the Company will participate in three upcoming investor conferences in March: Event: Cowen and Company 39 th Annual Health Care Conference Date: Monday, March 11 th
02/28/19
Summary ToggleSunesis Pharmaceuticals to Host Conference Call on March 7th to Discuss Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif. , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Thursday, March 7 th , 2019 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the fourth quarter and
01/17/19
Summary ToggleSunesis Announces Pricing of $20 Million Offering of Securities SOUTH SAN FRANCISCO, Calif. , Jan. 17, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced the pricing of underwritten public offerings of (i) 23,000,000 shares of its common stock and (ii) 17,000 shares of its non-voting Series E Convertible Preferred Stock
01/17/19
Summary ToggleSunesis Announces Proposed Public Offering of Common Stock and Preferred Stock SOUTH SAN FRANCISCO, Calif. , Jan. 17, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and Series E Convertible Preferred Stock in underwritten public
01/02/19
Summary ToggleSunesis Pharmaceuticals Announces Advancement into 100mg Cohort of Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies - 50 mg Cohort Completed - - Clinical Update Expected in the Second Quarter of 2019 - SOUTH SAN FRANCISCO, Calif. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the Company has opened the 100 mg cohort in the Phase 1b/2 trial of its non-covalent
12/02/18
Summary ToggleSunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at ASH Annual Meeting Results to be Further Discussed in Slide Webcast Today at 8:30 p.m. Pacific Time SOUTH SAN FRANCISCO, Calif. , Dec. 02, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the presentation of results from the Company’s Phase 1b/2 clinical trial of its non-covalent
11/28/18
Summary ToggleSunesis Pharmaceuticals to Provide Program Update for Non-Covalent BTK-Inhibitor Vecabrutinib at Analyst & Investor Event during ASH 2018 -Event on December 2 in San Diego, CA with Slide Webcast- SOUTH SAN FRANCISCO, Calif. , Nov. 28, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced it will provide a program update for vecabrutinib, the Company’s oral, reversible, non-covalent, BTK inhibitor which
11/19/18
Summary ToggleSunesis Pharmaceuticals to Present at the 30th Annual Piper Jaffray Healthcare Conference SOUTH SAN FRANCISCO, Calif. , Nov. 19, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Willie Quinn , Chief Financial Officer and Senior Vice President, Finance and Corporate Development of Sunesis, will present at the 30th Annual Piper Jaffray Healthcare
11/05/18
Summary ToggleSunesis Pharmaceuticals Reports Third Quarter 2018 Financial Results and Recent Highlights Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif. , Nov. 05, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the quarter ended September 30, 2018 . Loss from operations for the three and nine months
11/01/18
Summary ToggleSunesis Pharmaceuticals Announces Presentations at 60th American Society of Hematology Annual Meeting SOUTH SAN FRANCISCO, Calif. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced two poster presentations and an oral presentation at the 60 th American Society of Hematology (ASH) Annual Meeting being held December 1-4, 2018 in San Diego, California .
10/29/18
Summary ToggleSunesis Pharmaceuticals to Host Conference Call on November 5th to Discuss Third Quarter 2018 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif. , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Monday, November 5 th , 2018 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the third quarter ended
09/26/18
Summary ToggleSunesis Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference SOUTH SAN FRANCISCO, Calif. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Willie Quinn , Chief Financial Officer and Senior Vice President, Finance and Corporate Development of Sunesis, will present at the 2018 Cantor Global Healthcare
08/30/18
Summary ToggleSunesis Pharmaceuticals to Present at the Wells Fargo Securities 2018 Healthcare Conference

SOUTH SAN FRANCISCO, Calif. , Aug. 30, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Willie Quinn , Chief Financial Officer and Senior Vice President, Finance and Corporate Development of Sunesis, will present at the Wells Fargo Securities 2018

08/07/18
Summary ToggleSunesis Pharmaceuticals Reports Second Quarter 2018 Financial Results and Recent Highlights Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif. , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the quarter ended June 30, 2018 . Loss from operations for the three and six months ended
07/31/18
Summary ToggleSunesis Pharmaceuticals to Host Conference Call on August 7th to Discuss Second Quarter 2018 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif. , July 31, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Tuesday, August 7 th , 2018 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the second quarter ended

07/09/18
Summary ToggleSunesis Pharmaceuticals Strengthens Senior Management Team

SOUTH SAN FRANCISCO, Calif. , July 09, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced three key new management appointments as part of the Company’s expansion of its development team. Deepali Suri , M.Sc., a former Executive Director at Pharmacyclics (an AbbVie

06/25/18
Summary ToggleSunesis Pharmaceuticals Enters into $15.5 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC

SOUTH SAN FRANCISCO, Calif. , June 25, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it has entered into a Common Shares Purchase Agreement (the “Agreement”) of up to $15.5 million with Aspire Capital Fund, LLC (“Aspire Capital”).

06/18/18
Summary ToggleSunesis Pharmaceuticals Announces Presentations at the EHA Annual Meeting

Université Claude Bernard de Lyon Study Provides Preclinical Validation of Vecabrutinib Activity Against Ibrutinib-Resistant BTK C481S Mutated Lymphomas ERIC Study Shows Half of Ibrutinib-Relapse CLL Patients Carry BTK C481S Mutations SOUTH SAN FRANCISCO, Calif.

05/08/18
Summary ToggleSunesis Pharmaceuticals Reports First Quarter 2018 Financial Results and Recent Highlights

Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif. , May 08, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the first quarter ended March 31, 2018 . Loss from operations for the three months ended

05/01/18
Summary ToggleSunesis Pharmaceuticals to Host Conference Call on May 8th to Discuss First Quarter 2018 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif. , May 01, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Tuesday, May 8 th , 2018 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the first quarter ended March

03/14/18
Summary ToggleSunesis Pharmaceuticals to Present at Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif. , March 14, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the Company will present at two upcoming investor conferences. Willie Quinn , Chief Financial Officer and Senior Vice President, Finance and Corporate Development of
03/13/18
Summary ToggleSunesis Pharmaceuticals Announces Cancellation of Presentation and Webcast at Cowen & Company 38th Annual Health Care Conference Cancellation due to Travel Changes Caused by Inclement Weather Management to Proceed with Scheduled Investor Meetings via Conference Calls SOUTH SAN FRANCISCO, Calif. , March 13, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the cancellation of the company’s
03/08/18
Summary ToggleSunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Highlights Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif. , March 08, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the fourth quarter and year ended December 31, 2017 .
03/06/18
Summary ToggleSunesis Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference SOUTH SAN FRANCISCO, Calif. , March 06, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Willie Quinn , Chief Financial Officer and Senior Vice President, Finance and Corporate Development of Sunesis, will present at the Cowen and Company 38 th Annual Health
03/01/18
Summary ToggleSunesis Pharmaceuticals to Host Conference Call on March 8th to Discuss Fourth Quarter and Full-Year 2017 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif. , March 01, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Thursday, March 8th, 2018 at 1:30 p.m. Pacific Time to discuss corporate updates and financial results for the fourth quarter and year
02/07/18
Summary ToggleSunesis Pharmaceuticals Appoints Industry Veteran H. Ward Wolff to the Board of Directors SOUTH SAN FRANCISCO, Calif. , Feb. 07, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that H. Ward Wolff has been appointed to the Sunesis Board of Directors. Mr. Wolff brings over 40 years of finance and executive leadership experience to the Board, with 20
12/05/17
Summary ToggleSunesis Pharmaceuticals to Provide Program Update for Non-Covalent BTK Inhibitor SNS-062 at Analyst & Investor Event during ASH 2017 -Company announces vecabrutinib as generic name for SNS-062- -Event on December 9 in Atlanta, GA with Slide Webcast- SOUTH SAN FRANCISCO, Calif. , Dec. 05, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced it will provide a program update for SNS-062, generic name
12/04/17
Summary ToggleSunesis Pharmaceuticals Announces Change in Leadership - Daniel Swisher Resigns as CEO Effective End of 2017; t o Remain with Sunesis as a Strategic Advisor - - Board Member Dayton Misfeldt Appointed Interim CEO Effective January 2018 ; Board Starting Retained Search for Permanent Replacement - SOUTH SAN FRANCISCO, Calif. , Dec.
11/30/17
Summary ToggleSunesis Pharmaceuticals Appoints William Quinn as Chief Financial Officer and Senior Vice President, Finance and Corporate Development SOUTH SAN FRANCISCO, Calif. , Nov. 30, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the appointment of William Quinn as Chief Financial Officer and Senior Vice President, Finance and Corporate Development. Willie brings deep and relevant healthcare industry
11/02/17
Summary ToggleSunesis Pharmaceuticals Reports Third Quarter 2017 Financial Results and Recent Highlights Sunesis to Host Conference Call Today at 2:00 PM Eastern Time SOUTH SAN FRANCISCO, Calif. , Nov. 02, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the third quarter ended September 30, 2017 .
10/27/17
Summary ToggleSunesis to Host Conference Call on November 2nd to Discuss Third Quarter 2017 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif. , Oct. 27, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Thursday, November 2, 2017 at 2:00 p.m. Eastern Time to discuss corporate updates and financial results for the third quarter ended
10/25/17
Summary ToggleSunesis Announces Pricing of $20 Million Offering of Securities SOUTH SAN FRANCISCO, Calif. , Oct. 25, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the pricing of underwritten public offerings of (i) 7,500,000 shares of its common stock and accompanying warrants to purchase 3,750,000 shares of its common stock and (ii)
10/24/17
Summary ToggleSunesis Announces Proposed Public Offering of Common Stock, Preferred Stock and Warrants SOUTH SAN FRANCISCO, Calif. , Oct. 24, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and Series D Convertible Preferred Stock, each in combination with
08/31/17
Summary ToggleSunesis to Present at Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif. , Aug. 31, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the company will present at two upcoming investor conferences. Daniel Swisher , Chief Executive Officer of Sunesis, will present at the Wells Fargo Securities 2017
07/27/17
Summary ToggleSunesis Pharmaceuticals Reports Second Quarter 2017 Financial Results and Recent Highlights Sunesis to Host Conference Call Today at 2:00 PM Eastern Time SOUTH SAN FRANCISCO, Calif. , July 27, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the second quarter ended June 30, 2017 . Loss from operations for the three months ended
07/24/17
Summary ToggleSunesis to Host Conference Call on July 27th to Discuss Second Quarter 2017 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif. , July 24, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Thursday, July 27, 2017 at 2:00 p.m. Eastern Time to discuss corporate updates and financial results for the second quarter ended June
07/18/17
Summary ToggleSunesis Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062 in Adults with Chronic Lymphocytic Leukemia and other B-Cell Malignancies SOUTH SAN FRANCISCO, Calif. , July 18, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the first patient has been dosed at the Dana-Farber Institute in the Phase 1b/2 dose-escalation and cohort-expansion study of its reversible, non-covalent Bruton’s
06/26/17
Summary ToggleSunesis Pharmaceuticals Added to Russell Microcap® Index SOUTH SAN FRANCISCO, Calif. , June 26, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it was added to the Russell Microcap® Index when the Russell Investment Group reconstituted its family of U.S. indexes effective today, June 26, 2017 .
06/23/17
Summary ToggleSunesis Pharmaceuticals Announces Presentation of Updated Results from Washington University-Sponsored Phase 1/Cohort Expansion Trial of Vosaroxin Plus Azacitidine in Patients with MDS at the EHA Annual Meeting Vosaroxin Combination Demonstrates Encouraging Response Rates SOUTH SAN FRANCISCO, Calif. , June 23, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the presentation of updated results from a Washington University -sponsored Phase 1/Cohort Expansion trial of
05/08/17
Summary ToggleSunesis Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Highlights Sunesis to Host Conference Call Today at 2:00 PM Eastern Time SOUTH SAN FRANCISCO, Calif. , May 08, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the first quarter ended March 31, 2017 . Loss from operations for the three months ended
05/01/17
Summary ToggleSunesis Pharmaceuticals Announces Withdrawal of European Marketing Authorization Application (MAA) for Vosaroxin as a Treatment for Relapsed/Refractory AML Company’s Primary Development Focus is Non-Covalent Reversible BTK-Inhibitor SNS-062 Sunesis to Host Conference Call and Webcast in Conjunction with First Quarter 2017 Financial Results on Monday, May 8 th at 11:00 AM ET SOUTH SAN FRANCISCO, Calif. , May 01, 2017 (GLOBE NEWSWIRE) -- Sunesis
04/03/17
Summary ToggleSunesis Pharmaceuticals Announces Presentation of The Ohio State University-Sponsored Preclinical Study of BTK Inhibitor SNS-062 at AACR Annual Meeting SOUTH SAN FRANCISCO, Calif. , April 03, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced results from an Ohio State University -sponsored preclinical study evaluating the efficacy of non-covalent BTK inhibitor SNS-062 in chronic lymphocytic leukemia (CLL)
03/28/17
Summary ToggleSunesis Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference SOUTH SAN FRANCISCO, Calif. , March 28, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Eric Bjerkholt, Executive Vice President Corporate Development and Finance and Chief Financial Officer of Sunesis, will present at the 16 th Annual Needham Healthcare
03/22/17
Summary ToggleSunesis Pharmaceuticals Announces Submission of Responses to the EMA Day 180 List of Outstanding Issues for Marketing Authorization Application for Vosaroxin SOUTH SAN FRANCISCO, Calif. , March 22, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it has submitted its responses to the European Medicine Agency (EMA) Day 180 List of Outstanding Issues issued by the Committee for Medicinal Products for Human Use
03/09/17
Summary ToggleSunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial Results and Recent Highlights Sunesis to Host Conference Call Today at 11:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif. , March 09, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the fourth quarter and year ended December 31, 2016 .
03/02/17
Summary ToggleSunesis to Host Conference Call on March 9th to Discuss Fourth Quarter and Full-Year 2016 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif. , March 02, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Thursday, March 9, 2017 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the fourth quarter and year
03/01/17
Summary ToggleSunesis Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference SOUTH SAN FRANCISCO, Calif. , March 01, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher , Chief Executive Officer of Sunesis, will present at the Cowen and Company 37 th Annual Health Care Conference on Wednesday, March 8 th at 10:40 AM
02/06/17
Summary ToggleSunesis Pharmaceuticals to Present at the 19th Annual BIO CEO & Investor Conference SOUTH SAN FRANCISCO, Calif. , Feb. 06, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher , Chief Executive Officer of Sunesis, will present at the 19 th Annual BIO CEO & Investor Conference on Monday, February 13 th at 5:30 PM Eastern Time at
01/23/17
Summary ToggleSunesis Pharmaceuticals Announces Clinical and Regulatory Updates to SNS-062 and Vosaroxin Programs FDA Review of Investigational New Drug Application for SNS-062 Complete; Phase 1B/2 Study in Patients with Advanced B-Cell Malignancies to Begin Dosing in the First Half of 2017 Vosaroxin Day 180 List of Outstanding Issues Received; Company to go Before Scientific Advisory Group in April Prior to
12/05/16
Summary ToggleSunesis Pharmaceuticals Announces Presentation of Updated Results from the VALOR Trial Examining Overall Survival in Patients Age 60 Years and Older with Relapsed/Refractory AML at the ASH Annual Meeting SOUTH SAN FRANCISCO, Calif., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the presentation of updated results from the VALOR trial examining overall survival in patients age 60 years and older with relapsed/refractory AML.
12/05/16
Summary ToggleSunesis Pharmaceuticals Announces Presentation of Results from Completed Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK inhibitor SNS-062 at ASH Annual Meeting Program On Track to Begin Dosing in Phase 1B/2 Study of Patients with B-Cell Malignancies in the First Half of 2017 SOUTH SAN FRANCISCO, Calif. , Dec. 05, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the presentation of results from the Company’s Phase 1A
11/03/16
Summary ToggleSunesis Pharmaceuticals Announces Presentations at ASH Annual Meeting SOUTH SAN FRANCISCO, Calif. , Nov. 03, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced an oral and a poster presentation at the 58th American Society of Hematology Annual Meeting to be held December 3-6 in San Diego, California .
11/03/16
Summary ToggleSunesis Pharmaceuticals Reports Third Quarter 2016 Financial Results and Recent Highlights Sunesis to Host Conference Call Today at 11:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif. , Nov. 03, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the third quarter ended September 30, 2016 .
10/27/16
Summary ToggleSunesis to Host Conference Call on November 3rd to Discuss Third Quarter 2016 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif. , Oct. 27, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that it will host a conference call on Thursday, November 3, 2016 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the third quarter ended
10/24/16
Summary ToggleSunesis Announces Closing of Public Offerings and Full Exercise of Underwriters’ Option to Purchase Additional Shares SOUTH SAN FRANCISCO, Calif. , Oct. 24, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the closing of its previously announced underwritten offerings of (i) 5,675,825 shares of its common stock at a price of $3.85 per share, including the exercise in full of the
10/19/16
Summary ToggleSunesis Announces Pricing of $25 Million Offering of Securities SOUTH SAN FRANCISCO, Calif. , Oct. 19, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the pricing of underwritten offerings of (i) 4,935,500 shares of its common stock at a price of $3.85 per share, and (ii) 1,558 shares of its non-voting Series C Convertible
10/18/16
Summary ToggleSunesis Announces Proposed Public Offering of Common Stock and Preferred Stock SOUTH SAN FRANCISCO, Calif. , Oct. 18, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and Series C Convertible Preferred Stock in underwritten public
10/18/16
Summary ToggleSunesis Pharmaceuticals to Present at the Dawson James Securities 2nd Annual Small Cap Growth Stock Conference SOUTH SAN FRANCISCO, Calif. , Oct. 18, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Eric Bjerkholt, Chief Financial Officer of Sunesis, will present at the Dawson James Securities 2 nd Annual Small Cap Growth Stock Conference on Thursday, October 20 th
10/13/16
Summary ToggleSunesis Announces Submission of Responses to the EMA Day 120 List of Questions for Marketing Authorization Application for Vosaroxin SOUTH SAN FRANCISCO, Calif. , Oct. 13, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it has submitted its responses to European Medicines Agency (EMA) Day 120 List of Questions issued by the Committee for Medicinal Products for Human Use (CHMP) as part of
09/12/16
Summary ToggleSunesis Presents Dose Escalation Results from the Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK inhibitor SNS-062 Sunesis to Host Conference Call and Slide Webcast Today at 8:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif. , Sept. 12, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced results from the Company’s Phase 1A study in healthy volunteers evaluating oral non-covalent
09/07/16
Summary ToggleSunesis Pharmaceuticals Announces 1-for-6 Reverse Stock Split SOUTH SAN FRANCISCO, Calif. , Sept. 07, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a 1-for-6 reverse stock split, effective as of 5:00 p.m.
08/31/16
Summary ToggleSunesis to Present at Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif. , Aug. 31, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the Company will present at two upcoming investor conferences:  2016 Wells Fargo Healthcare Conference Wednesday, September 7 th at 2:20 PM Eastern Time The Westin Boston
08/25/16
Summary ToggleSunesis Announces Publication in "Drugs" Detailing Molecular and Pharmacologic Properties of Vosaroxin SOUTH SAN FRANCISCO, Calif. , Aug. 25, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the publication of an article detailing the molecular and pharmacologic properties of vosaroxin as a new therapeutic for acute myeloid leukemia (AML) in the journal Drugs .
07/29/16
Summary ToggleSunesis Pharmaceuticals Reports Second Quarter 2016 Financial Results and Recent Highlights Sunesis to Host Conference Call Today at 11:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif. , July 29, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the second quarter ended June 30, 2016 . Loss from operations for the three months ended
07/21/16
Summary ToggleSunesis to Host Conference Call on July 29th to Discuss Second Quarter 2016 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif. , July 21, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that it will host a conference call on Friday, July 29, 2016 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the second quarter ended June
07/05/16
Summary ToggleSunesis Pharmaceuticals to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference SOUTH SAN FRANCISCO, Calif. , July 05, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher , Chief Executive Officer of Sunesis, will present at Cantor Fitzgerald’s 2 nd Annual Healthcare Conference on Tuesday, July 12 th at 1:00 PM Eastern Time
06/13/16
Summary ToggleSunesis Pharmaceuticals Announces Presentation of Positive Results from MD Anderson Sponsored Trial in Frontline Elderly AML and MDS at the EHA Annual Meeting SOUTH SAN FRANCISCO, Calif. , June 13, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals (NASDAQ:SNSS) today announced the presentation of updated results from an ongoing Phase 1b/2 University of Texas MD Anderson Cancer Center-sponsored trial of vosaroxin in combination with decitabine in older
06/06/16
Summary ToggleSunesis Announces Study Examining the Value of Complete Remission Prior to HCT in Patients with AML Presented at 2016 ASCO Annual Meeting Study Funded Jointly by Sunesis and the Center for International Blood and Marrow Transplant Research SOUTH SAN FRANCISCO, Calif. , June 06, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced the presentation of results from a study conducted by the Center for
06/01/16
Summary ToggleSunesis Pharmaceuticals Appoints Linda Neuman, M.D., as Vice President, Clinical Development SOUTH SAN FRANCISCO, Calif. , June 01, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that Linda Neuman , M.D., has been appointed to the role of Vice President, Clinical Development. Dr. Neuman brings 10 years of clinical practice and 13 years of industry
05/25/16
Summary ToggleSunesis Pharmaceuticals Announces Support of First-Ever Acute Myeloid Leukemia Awareness Month in June Sunesis Provides Educational Grant to Support Campaign Sponsor Cancer Care SOUTH SAN FRANCISCO, Calif. , May 25, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced its support for the first-ever Acute Myeloid Leukemia Awareness Month to be held in June.  The goal
05/19/16
Summary ToggleSunesis Pharmaceuticals Announces Oral Presentation on Vosaroxin at the 21st Congress of the European Hematology Association SOUTH SAN FRANCISCO, Calif. , May 19, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced an oral presentation on vosaroxin at the 21 st Congress of the European Hematology Association (EHA) to be held June 9-12, 2016 at the Bella Center in Copenhagen, Denmark .
05/18/16
Summary ToggleSunesis to Present at the 2016 UBS Global Healthcare Conference SOUTH SAN FRANCISCO, Calif. , May 18, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher , Chief Executive Officer of Sunesis, will present at the 2016 UBS Global Healthcare Conference on Wednesday, May 25 th at 11:00 AM Eastern Time at The
05/05/16
Summary ToggleSunesis Pharmaceuticals Reports First Quarter 2016 Financial Results and Recent Highlights Sunesis to Host Conference Call Today at 11:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif. , May 05, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the first quarter ended March 31, 2016 . Loss from operations for the three months ended
04/28/16
Summary ToggleSunesis to Host Conference Call on May 5th to Discuss First Quarter 2016 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif. , April 28, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that it will host a conference call on Thursday, May 5, 2016 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the first quarter ended March
04/05/16
Summary ToggleSunesis Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference SOUTH SAN FRANCISCO, Calif. , April 05, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher , Chief Executive Officer of Sunesis, will present at the 15th Annual Needham Healthcare Conference on Tuesday, April 12 th at 1:40 PM Eastern Time at The
04/01/16
Summary ToggleSunesis Pharmaceuticals Announces Closing of $15 Million Venture Loan SOUTH SAN FRANCISCO, Calif. , April 01, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it has entered into a $15 million loan agreement (“the agreement”) with Bridge Bank , a division of Western Alliance Bank and Solar Capital Ltd.
03/28/16
Summary ToggleSunesis Pharmaceuticals Appoints Geoffrey Parker to the Board of Directors SOUTH SAN FRANCISCO, Calif. , March 28, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Geoffrey Parker has been appointed to the Sunesis Board of Directors.  Mr. Parker brings over 30 years of finance and executive leadership experience to the Board
03/24/16
Summary ToggleSunesis Pharmaceuticals Announces First Patient Treated in Vanderbilt University-Sponsored Phase 2 VITAL Study of Vosaroxin in Combination with Infusional Cytarabine in Patients with Previously Untreated AML Trial to be Conducted at the Vanderbilt-Ingram Cancer Center SOUTH SAN FRANCISCO, Calif. , March 24, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the first patients have been treated in the investigator-sponsored VITAL ( V osaroxin and I nfusional
03/23/16
Summary ToggleSunesis Pharmaceuticals Announces First Subject Dosed in Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062 Study Start Marks Sunesis’ Second Kinase Inhibitor Program to Enter the Clinic SOUTH SAN FRANCISCO, Calif. , March 23, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the first subject has been dosed in a Phase 1A, randomized, double-blind,
03/10/16
Summary ToggleSunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2015 Financial Results and Recent Highlights Sunesis to Host Conference Call Today at 11:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif. , March 10, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the fourth quarter and year ended December 31, 2015 .
03/03/16
Summary ToggleSunesis to Host Conference Call on March 10th to Discuss Fourth Quarter and Full-Year 2015 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif. , March 03, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Thursday, March 10, 2016 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the fourth quarter and year
03/01/16
Summary ToggleSunesis Pharmaceuticals to Present at the Cowen and Company 36th Annual Health Care Conference SOUTH SAN FRANCISCO, Calif. , March 01, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher , Chief Executive Officer of Sunesis, will present at the Cowen and Company 36 th Annual Health Care Conference on Tuesday, March 8 th at 8:00 AM Eastern
02/19/16
Summary ToggleSunesis Pharmaceuticals Announces Promotion of Deborah A. Thomas, Ph.D., to Senior Vice President, Regulatory Affairs, Quality Assurance, and Non-Clinical Development SOUTH SAN FRANCISCO, Calif. , Feb. 19, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the promotion of Deborah A. Thomas , Ph.D., to the role of Senior Vice President, Regulatory Affairs, Quality Assurance, and Non-Clinical Development .
01/04/16
Summary ToggleSunesis Pharmaceuticals Announces European Medicines Agency Validates Marketing Authorization Application for Vosaroxin in AML SOUTH SAN FRANCISCO, Calif. , Jan. 04, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for vosaroxin as a treatment for relapsed refractory acute myeloid
12/21/15
Summary ToggleSunesis Announces Closing of $26 Million Offering of Securities and Exercise of Underwriter’s Over-Allotment Option SOUTH SAN FRANCISCO, Calif. , Dec. 21, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the closing of underwritten offerings of (i) 10,996,191 shares of its common stock, that included the exercise of the underwriter's over-allotment option of 1,434,286 shares,
12/16/15
Summary ToggleSunesis Announces Pricing of $25 Million Offering of Securities SOUTH SAN FRANCISCO, Calif. , Dec. 16, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the pricing of underwritten offerings of (i) 9,561,905 shares of its common stock at a price of $0.84 per share, and (ii) 20,200 shares of its non-voting Series B Convertible
12/08/15
Summary ToggleSunesis Pharmaceuticals Announces Submission of a Marketing Authorization Application for Vosaroxin for the Treatment of Acute Myeloid Leukemia in Europe SOUTH SAN FRANCISCO, Calif. , Dec. 8, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the company has submitted a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for Vosaroxin for the treatment of acute myeloid leukemia in
12/07/15
Summary ToggleSunesis Pharmaceuticals Announces Presentation of Positive Results From MD Anderson Sponsored Trial in AML at ASH Annual Meeting SOUTH SAN FRANCISCO, Calif. , Dec. 7, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the presentation of updated results from an ongoing Phase 1b/2 University of Texas MD Anderson cancer Center-sponsored trial of vosaroxin in combination with decitabine in
12/06/15
Summary ToggleSunesis Pharmaceuticals Announces Presentation of Results From Washington University Sponsored Phase 1/2 Trial of Vosaroxin in MDS and VALOR Analysis of Baseline Safety Predictors at ASH Annual Meeting SOUTH SAN FRANCISCO, Calif. , Dec. 6, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the presentation of results from a Washington University -sponsored Phase 1 trial of vosaroxin plus azacitidine in patients with myelodysplastic syndrome, and from an analysis
12/03/15
Summary ToggleSunesis Partners With Clinigen Group to Initiate a Compassionate Use Program for Patients With Relapsed or Refractory Acute Myeloid Leukemia SOUTH SAN FRANCISCO, Calif., Dec. 3, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that it has initiated a Compassionate Use Program for vosaroxin. The Compassionate Use Program will be made available to eligible patients in the U.S.
12/01/15
Summary ToggleSunesis Pharmaceuticals Announces First Patient Treated in Indiana University Pilot Study of Vosaroxin and Cytarabine in Adults Age 60 Years and Older With Previously Untreated AML Trial to be Conducted at the Melvin and Bren Simon Cancer Center at Indiana University SOUTH SAN FRANCISCO, Calif. , Dec. 1, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the first patient has been treated in an investigator-sponsored pilot study of
11/30/15
Summary ToggleSunesis Pharmaceuticals Announces European Patent Covering Vosaroxin Combination Use in AML and Other Hematologic Malignancies SOUTH SAN FRANCISCO, Calif. , Nov. 30, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the European Patent Office (EPO) has granted European Patent No. 2 049 109 B1, claiming certain combined uses of vosaroxin and cytarabine, at doses of 10-120 mg/m 2 and
11/09/15
Summary ToggleSunesis Pharmaceuticals Presents Preclinical Data From Its BTK and PDK1 Inhibitor Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics SOUTH SAN FRANCISCO, Calif. , Nov. 9, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that two posters detailing preclinical data from its BTK and PDK1 inhibitor programs were presented on Sunday, November 8 th at the AACR-NCI-EORTC International Conference on
11/05/15
Summary ToggleSunesis Pharmaceuticals Announces Presentations at ASH Annual Meeting SOUTH SAN FRANCISCO, Calif. , Nov. 5, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced one oral presentation and two poster presentations at the 57 th American Society of Hematology Annual Meeting to be held December 5-8 in Orlando, Florida .
11/05/15
Summary ToggleSunesis Pharmaceuticals Reports Third Quarter 2015 Financial Results and Recent Highlights Sunesis to Host Conference Call Today at 11:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif. , Nov. 5, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the third quarter ended September 30, 2015 .
11/04/15
Summary ToggleSunesis Pharmaceuticals Announces Presentation of Responder Survival Analysis from Phase 3 VALOR Trial at the 2015 Chemotherapy Foundation Symposium SOUTH SAN FRANCISCO, Calif. , Nov. 4, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the presentation of a responder survival analysis from the Phase 3 VALOR trial at the 33 rd Annual Chemotherapy Foundation Symposium (CFS) taking place at the Marriott Marquis
10/29/15
Summary ToggleSunesis to Host Conference Call on November 5th to Discuss Third Quarter 2015 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif. , Oct. 29, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that it will host a conference call on Thursday, November 5, 2015 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the third quarter ended
10/27/15
Summary ToggleSunesis Pharmaceuticals Announces Presentations at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics SOUTH SAN FRANCISCO, Calif. , Oct. 27, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced two poster presentations at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held November 5-9 in Boston, Massachusetts .
10/15/15
Summary ToggleSunesis Pharmaceuticals Announces Oral Presentation of VALOR Analysis at the 77th Annual Meeting of the Japanese Society of Hematology SOUTH SAN FRANCISCO, Calif. , Oct. 15, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that data from the company's VALOR trial evaluating vosaroxin in older patients with acute myeloid leukemia (AML) will be presented at the AML Clinical Trial Oral Session of
10/07/15
Summary ToggleSunesis Announces Anticipated Submission of European Marketing Authorization Application for Vosaroxin in AML Before Year End Company Also Announces Executive Management Team Changes Dr. Adam R. Craig to Step Down as Chief Medical Officer Following Transition Period Jennifer Smith Appointed Vice President, Biometrics SOUTH SAN FRANCISCO, Calif. , Oct. 7, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc.
08/05/15
Summary ToggleSunesis Pharmaceuticals to Present at the 2015 Wedbush PacGrow Healthcare Conference SOUTH SAN FRANCISCO, Calif. , Aug. 5, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher , Chief Executive Officer of Sunesis, will present at the 2015 Wedbush PacGrow Healthcare Conference on Wednesday, August 12 th  at 10:20 AM Eastern
08/04/15
Summary ToggleSunesis Announces Publication of Vosaroxin Phase 3 VALOR Trial Results in The Lancet Oncology SOUTH SAN FRANCISCO , Aug. 4, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that results from the Company's Phase 3 VALOR trial of vosaroxin and cytarabine in 711 patients with relapsed or refractory acute myeloid leukemia (AML) were published in the The
07/30/15
Summary ToggleSunesis Pharmaceuticals Reports Second Quarter 2015 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif. , July 30, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the second quarter ended June 30, 2015 . Loss from operations for the three and six months ended June 30, 2015 was $10.6 million and $19.4 million ,
07/23/15
Summary ToggleSunesis Pharmaceuticals Announces Regulatory Update Company to Proceed Expeditiously With Marketing Authorization Application in Europe and Will Evaluate Regulatory and Clinical Strategies to Gain Marketing Approval in the U.S. Sunesis to Host Conference Call Today at 5:00 PM Eastern Time SOUTH SAN FRANCISCO, Calif.
07/01/15
Summary ToggleSunesis to Present at Cantor Fitzgerald's Inaugural Healthcare Conference SOUTH SAN FRANCISCO, Calif. , July 1, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher , Chief Executive Officer of Sunesis, will present at the Cantor Fitzgerald Inaugural Healthcare Conference on Wednesday, July 8 th at 9:00 AM Eastern Time
06/12/15
Summary ToggleSunesis Pharmaceuticals Presents New Data From VALOR Evaluating Vosaroxin in Older Patients With Acute Myeloid Leukemia at the 20th Congress of the European Hematology Association Sunesis to Host Conference Call and Webcast Today at 10:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif. , June 12, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) announced today additional results of the VALOR trial, a Phase 3 study of vosaroxin and cytarabine in adult patients
05/31/15
Summary ToggleSunesis Pharmaceuticals Announces Presentation of VALOR Trial Subgroup Analysis at ASCO 2015 Annual Meeting Post Hoc Analysis Shows Promising Outcomes for Vosaroxin/Cytarabine-Treated Patients Age 60 Years and Older Who Received Bone Marrow Transplants SOUTH SAN FRANCISCO, Calif. , May 31, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced results from a post hoc
05/21/15
Summary ToggleSunesis Pharmaceuticals Announces Presentations of VALOR Data at the 20th Congress of the European Hematology Association Sunesis to Host Conference Call and Webcast Friday, June 12 at 10:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif. , May 21, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that two poster presentations describing results from the VALOR trial will be presented at
05/14/15
Summary ToggleSunesis Pharmaceuticals Announces Presentation of VALOR Data at the 2015 ASCO Annual Meeting Presentation to Highlight Results From Post Hoc Analysis of Patients Age 60 Years and Older Undergoing Post-Treatment Transplant SOUTH SAN FRANCISCO, Calif. , May 14, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that results from a post hoc subgroup analysis
05/13/15
Summary ToggleSunesis to Present at the 2015 UBS Global Health Care Conference SOUTH SAN FRANCISCO, Calif. , May 13, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher , Chief Executive Officer of Sunesis, will present at the 2015 UBS Global Health Care Conference on Tuesday, May 19 th at 4:30 PM Eastern Time at the
05/05/15
Summary ToggleSunesis Pharmaceuticals Reports First Quarter 2015 Financial Results and Recent Highlights Sunesis to Host Conference Call Today at 11:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif. , May 5, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the first quarter ended March 31, 2015 . Loss from operations for the three months ended
04/28/15
Summary ToggleSunesis to Host Conference Call on May 5th to Discuss First Quarter 2015 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif. , April 28, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Tuesday, May 5, 2015 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the first quarter ended March
03/12/15
Summary ToggleSunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2014 Financial Results and Recent Highlights Sunesis to Host Conference Call Today at 11:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif. , March 12, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the fourth quarter and year ended December 31, 2014 .
03/05/15
Summary ToggleSunesis to Host Conference Call on March 12th to Discuss Fourth Quarter and Full-Year 2014 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif. , March 5, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Thursday, March 12, 2015 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the fourth quarter and year
03/02/15
Summary ToggleSunesis Announces Amendment to Loan Agreement SOUTH SAN FRANCISCO, Calif. , March 2, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the signing of an amendment to its loan and security agreement (the "Loan Agreement") with Oxford Finance LLC , Silicon Valley Bank , and Horizon Technology Finance
02/24/15
Summary ToggleSunesis to Present at Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif. , Feb. 24, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher , Chief Executive Officer and President of Sunesis, will present at two upcoming investor conferences: Cowen & Company 35 th Annual Health Care Conference
02/18/15
Summary ToggleSunesis to Present at the 2015 RBC Capital Markets' Global Healthcare Conference SOUTH SAN FRANCISCO, Calif. , Feb. 18, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Eric Bjerkholt, Executive Vice President of Corporate Development and Finance and Chief Financial Officer of Sunesis, will present at the 2015 RBC Capital Markets' Global
12/08/14
Summary ToggleSunesis Announces Presentation of Positive Updated Results from Ongoing MD Anderson-Sponsored Trial of Vosaroxin in AML and High-Risk MDS at ASH Annual Meeting SOUTH SAN FRANCISCO, Calif. , Dec. 8, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the presentation of updated results from an ongoing Phase 1b/2 University of Texas MD Anderson Cancer Center-sponsored trial of vosaroxin in combination with decitabine in
12/07/14
Summary ToggleSunesis Pharmaceuticals Announces Presentation of Results From Phase 3 VALOR Trial at ASH Annual Meeting Sunesis to Host Conference Call and Webcast Tuesday, December 9 at 10:30 AM Pacific Time SOUTH SAN FRANCISCO, Calif. , Dec. 7, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that results from the Company's Phase 3 VALOR trial of vosaroxin and cytarabine in
12/02/14
Summary ToggleSunesis Pharmaceuticals to Host Conference Call and Slide Webcast Tuesday, December 9 Following Presentation of Phase 3 VALOR Trial Results at ASH Annual Meeting SOUTH SAN FRANCISCO, Calif. , Dec. 2, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call and slide webcast on Tuesday, December 9, 2014 at 10:30 AM Pacific Time to discuss the presentation of results from the Company's Phase 3
11/24/14
Summary ToggleSunesis Announces Publication of REVEAL-1 Trial Results in the British Journal of Haematology SOUTH SAN FRANCISCO, Calif. , Nov. 24, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the publication of results from the Company's REVEAL-1 (Response Evaluation of Vosaroxin in Elderly AmL) trial, a Phase 2 trial of single agent vosaroxin in previously
11/19/14
Summary ToggleSunesis Announces Publication of Vosaroxin Phase 1b/2 AML Trial Results in Haematologica SOUTH SAN FRANCISCO, Calif. , Nov. 19, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the online publication of results from the Company's Phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid
11/17/14
Summary ToggleSunesis Pharmaceuticals Announces Late-Breaking Presentation of Phase 3 VALOR Trial at ASH Annual Meeting SOUTH SAN FRANCISCO, Calif. , Nov. 17, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that results from the Company's Phase 3 VALOR trial of vosaroxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia (AML) will be presented in a
11/10/14
Summary ToggleSunesis Pharmaceuticals Reports Third Quarter 2014 Financial Results and Recent Highlights Announces Submission of Letter of Intent to File MAA for Vosaroxin in Relapsed or Refractory AML With the European Medicines Agency Announces Upcoming Presentations at ASH Annual Meeting, EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Sunesis to Host Conference Call Today at
11/05/14
Summary ToggleSunesis to Present at Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif. , Nov. 5, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher , Chief Executive Officer and President of Sunesis, will present at two upcoming investor conferences: Credit Suisse Annual Healthcare Conference Wednesday,
11/03/14
Summary ToggleSunesis to Host Conference Call on November 10th to Discuss Third Quarter 2014 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif. , Nov. 3, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced it will host a conference call on Monday, November 10, 2014 at 10:30 am Eastern Time to discuss corporate updates and financial results for the third quarter ended September
10/06/14
Summary ToggleSunesis Announces Results From Pivotal Phase 3 VALOR Trial of Vosaroxin and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia Trial Does Not Reach Primary Endpoint of Statistically Significant Improvement in Overall Survival Shows Significant Survival Benefit when Censored for Transplant Safety Profile Consistent with that Observed in Previous Company Trials Company Plans to Commence European Filing and Explore U.S.
09/04/14
Summary ToggleSunesis to Present at the 2014 Morgan Stanley Global Healthcare Conference SOUTH SAN FRANCISCO, Calif. , Sept. 4, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher , Chief Executive Officer of Sunesis, will be presenting at the 2014 Morgan Stanley Global Healthcare Conference on Wednesday, September 10, 2014 at 9:10
08/06/14
Summary ToggleSunesis to Present at the 2014 Wedbush Life Sciences Management Access Conference SOUTH SAN FRANCISCO, Calif. , Aug. 6, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher , Chief Executive Officer of Sunesis, will be presenting at the 2014 Wedbush Life Sciences Management Access Conference on Tuesday, August 12, 2014 at 9:10
08/05/14
Summary ToggleSunesis Pharmaceuticals Reports Second Quarter 2014 Financial Results and Recent Highlights VALOR Trial Reaches Prespecified Events for Unblinding Sunesis to Host Conference Call Today at 11:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif. , Aug. 5, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the quarter ended June 30, 2014 .
07/29/14
Summary ToggleSunesis to Host Conference Call on August 5th to Discuss Second Quarter 2014 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif. , July 29, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Tuesday, August 5, 2014 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the second quarter ended June
07/09/14
Summary ToggleSunesis Pharmaceuticals Announces European Medicines Agency Acceptance of Pediatric Investigation Plan for QINPREZO™ (Vosaroxin) for AML SOUTH SAN FRANCISCO, Calif. , July 9, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the Pediatric Committee of the European Medicines Agency (EMA) has issued a positive opinion on the Company's Pediatric Investigation Plan (PIP) for QINPREZO TM
06/11/14
Summary ToggleSunesis to Present at the 2014 Wells Fargo Healthcare Conference SOUTH SAN FRANCISCO, Calif. , June 11, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Eric Bjerkholt, Executive Vice President, Corporate Development and Finance at Sunesis, will be presenting at the 2014 Wells Fargo Healthcare Conference on Tuesday, June
06/02/14
Summary ToggleSunesis Announces Presentation of Positive Updated Results From Ongoing MD Anderson-Sponsored Trial of Vosaroxin in AML and High-Risk MDS at ASCO 2014 Annual Meeting SOUTH SAN FRANCISCO, Calif. , June 2, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the presentation of updated results from an ongoing Phase 1b/2 University of Texas MD Anderson Cancer Center-sponsored trial of Qinprezo™ (vosaroxin) in combination with
05/14/14
Summary ToggleSunesis to Present at Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif. , May 14, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the company will present at two upcoming investor conferences. Daniel Swisher , Chief Executive Officer of Sunesis, will present at the UBS Global Healthcare Conference on
05/07/14
Summary ToggleSunesis Pharmaceuticals Reports First Quarter 2014 Financial Results and Recent Highlights Receives FDA Acceptance for Trademark Name Qinprezo™ Sunesis to Host Conference Call Today at 11:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif. , May 7, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the quarter ended March 31, 2014 .
04/30/14
Summary ToggleSunesis to Host Conference Call on May 7th to Discuss First Quarter 2014 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif. , April 30, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Wednesday, May 7, 2014 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the first quarter ended March
04/22/14
Summary ToggleSunesis Announces MD Anderson Sponsored Study of Vosaroxin in AML and High-Risk MDS Poster to be Presented at ASCO 2014 SOUTH SAN FRANCISCO, Calif. , April 22, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that updated data from the ongoing Phase 1b/2 University of Texas MD Anderson Cancer Center-sponsored study of vosaroxin in combination with decitabine in older patients with
04/08/14
Summary ToggleSunesis Announces Presentation of Positive Results From Ongoing MD Anderson-Sponsored Trial of Vosaroxin in AML and High-Risk MDS Data Presented at AACR 2014 Annual Meeting Company to Host Conference Call Today at 8:00 AM Pacific Time SOUTH SAN FRANCISCO, Calif. , April 8, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the presentation of results from an ongoing Phase 1b/2 University of
04/02/14
Summary ToggleSunesis Announces MD Anderson Sponsored Trial of Vosaroxin in AML and High-Risk MDS Poster to be Presented at AACR 2014 Company to Host Conference Call on April 8th to Discuss Updated Data SOUTH SAN FRANCISCO, Calif. , April 2, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that updated data from the ongoing Phase 1b/2 University of Texas MD Anderson Cancer Center-sponsored
03/06/14
Summary ToggleSunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results and Recent Highlights Phase 1b/2 Data From MD Anderson Sponsored Study of Vosaroxin in AML and High-Risk MDS to be Presented at the AACR Annual Meeting 2014 Sunesis to Host Conference Call Today at 11:00AM Eastern Time SOUTH SAN FRANCISCO, Calif. , March 6, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc.
02/28/14
Summary ToggleSunesis to Present at Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif. , Feb. 28, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher , Chief Executive Officer and President of Sunesis, will present at two upcoming investor conferences; Cowen & Company 34th Annual Health Care Conference
02/28/14
Summary ToggleSunesis to Host Conference Call on March 6th to Discuss Fourth Quarter and Full-Year 2013 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif. , Feb. 28, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Thursday, March 6, 2014 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the fourth quarter and year
02/27/14
Summary ToggleSunesis Announces Pricing of a $43.0 Million Public Offering of Common Stock and Warrants Total Gross Proceeds of $138.3 Million Assuming the Potential Exercise of All Warrants SOUTH SAN FRANCISCO, Calif. , Feb. 27, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the pricing of an underwritten public offering of 4,650,000 shares of common stock
02/26/14
Summary ToggleSunesis Announces Proposed Public Offering of Common Stock and Warrants SOUTH SAN FRANCISCO, Calif. , Feb. 26, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and warrants to purchase shares of its common stock in an underwritten
02/10/14
Summary ToggleSunesis Appoints Joseph I. DePinto as Chief Commercial Officer, Updates VALOR Timeline to Unblinding of Data SOUTH SAN FRANCISCO, Calif. , Feb. 10, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the appointment of Joseph I. DePinto to the newly created position of Executive Vice President and Chief Commercial Officer. Mr.
02/06/14
Summary ToggleSunesis to Present at Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif. , Feb. 6, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher , Chief Executive Officer and President of Sunesis, will present at two upcoming investor conferences; Leerink Global Healthcare Conference Thursday,
01/09/14
Summary ToggleSunesis Pharmaceuticals Expands Hematology Franchise With Global Licenses to Two Kinase Inhibitor Programs BTK Inhibitor SNS-062 Licensed from Biogen Idec ; IND Anticipated in Approximately 12 Months PDK1 Inhibitor Program Licensed from Millennium; Development Candidate Selection to Take Place in 2014 Sunesis to Host Conference Call, Provide 2014 Outlook, Today at 11AM Eastern Time SOUTH SAN FRANCISCO,
12/10/13
Summary ToggleSunesis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Trial Evaluating Vosaroxin in Combination With Azacitidine in MDS Cardiff University-Sponsored LI-1 Trial Combination Arm Evaluated by DMEC SOUTH SAN FRANCISCO, Calif. , Dec. 10, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the initiation of an investigator-sponsored trial of vosaroxin in combination with azacitidine in
11/27/13
Summary ToggleSunesis Pharmaceuticals to Present at the Piper Jaffray 25th Annual Healthcare Conference SOUTH SAN FRANCISCO, Calif. , Nov. 27, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher , Chief Executive Officer and President of Sunesis, will be presenting at the Piper Jaffray 25th Annual Healthcare Conference on Tuesday, December 3rd at
11/12/13
Summary ToggleSunesis Pharmaceuticals Reports Third Quarter Financial Results and Recent Highlights Sunesis to Host Conference Call Today at 11AM Eastern Time SOUTH SAN FRANCISCO, Calif. , Nov. 12, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the quarter ended September 30, 2013 . Loss from operations for the three and nine months ended
11/06/13
Summary ToggleSunesis to Present at the 2013 Credit Suisse Annual Health Care Conference SOUTH SAN FRANCISCO, Calif. , Nov. 6, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher , Chief Executive Officer and President of Sunesis, will be presenting at the 2013 Credit Suisse Annual Health Care Conference on Wednesday, November 13th
11/05/13
Summary ToggleSunesis to Host Conference Call on November 12th to Discuss Third Quarter Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif. , Nov. 5, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Tuesday, November 12, 2013 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the third quarter ended
10/30/13
Summary ToggleSunesis Pharmaceuticals Announces Initiation of Phase 2 Cohort of MD Anderson Sponsored Study of Vosaroxin in AML and High-Risk MDS Phase 1b Cohort Demonstrates Good Tolerability and Objective Responses SOUTH SAN FRANCISCO, Calif. , Oct. 30, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the initiation of the Phase 2 cohort of the Phase 1b/2, MD Anderson Cancer Center -sponsored study of
10/28/13
Summary ToggleSunesis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Phase I/II Trial Evaluating Vosaroxin in Myelodysplastic Syndrome SOUTH SAN FRANCISCO, Calif. , Oct. 28, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the initiation of a Phase I/II investigator-sponsored trial of vosaroxin, the company's lead product candidate, in adult patients with previously treated intermediate-2 or
09/25/13
Summary ToggleSunesis Pharmaceuticals Completes Enrollment in Phase 3 VALOR Trial of Vosaroxin in AML Unblinding of Largest Company-Sponsored Trial in First Relapsed/Refractory AML Expected First Half 2014 SOUTH SAN FRANCISCO, Calif., Sep 25, 2013 (GLOBE NEWSWIRE via COMTEX) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that enrollment in the company's pivotal, Phase 3 VALOR trial
09/19/13
Summary ToggleSunesis to Present at BioCentury's 2013 Newsmakers in the Biotech Industry Conference SOUTH SAN FRANCISCO, Calif. , Sept. 19, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher , Chief Executive Officer and President of Sunesis, will be presenting at BioCentury's 2013 Newsmakers in the Biotech Industry Conference on Friday,
09/04/13
Summary ToggleSunesis to Present at the 2013 Stifel Nicolaus Healthcare Conference SOUTH SAN FRANCISCO, Calif. , Sept. 4, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher , Chief Executive Officer and President of Sunesis, will be presenting at the 2013 Stifel Nicolaus Healthcare Conference on Wednesday, September 11 th at
08/07/13
Summary ToggleSunesis to Present at the 2013 Wedbush Life Sciences Management Access Conference SOUTH SAN FRANCISCO, Calif. , Aug. 7, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Eric Bjerkholt, Executive Vice President, Corporate Development and Finance, Chief Financial Officer at Sunesis, will be presenting at the 2013 Wedbush Life Sciences
07/29/13
Summary ToggleSunesis Pharmaceuticals Reports Second Quarter Financial Results and Recent Highlights VALOR Enrollment Exceeds 675 Patients Cardiff University-Sponsored LI-1 Trial Monotherapy Treatment Arm Evaluated by DMEC Investigator-Sponsored Phase I/II Trial Evaluating Vosaroxin in Combination with Decitabine in AML and MDS Initiated at MD Anderson Cancer Center Sunesis to Host Conference Call
06/13/13
Summary ToggleData and Safety Monitoring Board Recommends Continuation of Sunesis Pharmaceuticals' VALOR Trial With no Change to Study Conduct SOUTH SAN FRANCISCO, Calif. , June 13, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the independent Data and Safety Monitoring Board (DSMB) for the VALOR trial has completed its latest periodic safety review and recommended that the trial continue as
06/12/13
Summary ToggleSunesis to Present at the Wells Fargo 2013 Healthcare Conference SOUTH SAN FRANCISCO, Calif. , June 12, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Eric Bjerkholt, Executive Vice President, Corporate Development and Finance, Chief Financial Officer at Sunesis, will be presenting at the Wells Fargo 2013 Healthcare
06/11/13
Summary ToggleSunesis Pharmaceuticals Appoints Steve Carchedi to Board of Directors SOUTH SAN FRANCISCO, Calif. , June 11, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Steve Carchedi has been appointed to the Sunesis Board of Directors, effective immediately. Currently, Mr. Carchedi serves as the President, Commercial Operations for
05/30/13
Summary ToggleVosaroxin Review Published in Expert Opinion on Pharmacotherapy SOUTH SAN FRANCISCO, Calif. , May 30, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the publication of a peer-reviewed paper in Expert Opinion on Pharmacotherapy featuring the Company's lead product candidate, vosaroxin.
05/10/13
Summary ToggleSunesis to Present at Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., May 10, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the Company will present at two upcoming investor conferences. Dan Swisher , Chief Executive Officer of Sunesis, will present at the Bank of America Merrill Lynch Health
05/09/13
Summary ToggleSunesis Pharmaceuticals Reports First Quarter Financial Results and Recent Highlights Sunesis to Host Conference Call Today at 11:00AM Eastern Time SOUTH SAN FRANCISCO, Calif. , May 9, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the quarter ended March 31, 2013 . Loss from operations for the three months ended March 31,
05/02/13
Summary ToggleSunesis to Host Conference Call on May 9th to Discuss First Quarter Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif. , May 2, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Thursday, May 9, 2013 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the first quarter ended March 31,
04/24/13
Summary ToggleSunesis to Present at the Needham & Company 12th Annual Healthcare Conference SOUTH SAN FRANCISCO, Calif. , April 24, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher , Chief Executive Officer of Sunesis, will be presenting at the Needham & Company 12 th Annual Healthcare Conference on Wednesday, May 1, 2013 at 8:00 AM
03/13/13
Summary ToggleSunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2012 Financial Results and Recent Highlights Sunesis to Host Conference Call Today at 11:00AM Eastern Time SOUTH SAN FRANCISCO, Calif. , March 13, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the fourth quarter and year ended December 31, 2012 .
03/11/13
Summary ToggleSunesis to Present at the 25th Annual Roth Conference SOUTH SAN FRANCISCO, Calif. , March 11, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Adam R. Craig , M.D., Ph.D., Executive Vice President, Development and Chief Medical Officer of Sunesis, will be presenting at the 25th Annual Roth Conference on
03/06/13
Summary ToggleSunesis to Host Conference Call on March 13th to Discuss Fourth Quarter and Full-Year 2012 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif., March 6, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Wednesday, March 13th, 2013 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the fourth quarter and year
02/20/13
Summary ToggleSunesis to Present at Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Feb. 20, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer of Sunesis, will present at two upcoming investor conferences: RBC Capital Markets 2013 Global Healthcare Conference Tuesday,
02/06/13
Summary ToggleSunesis to Present at the Leerink Swann 2013 Global Healthcare Conference SOUTH SAN FRANCISCO, Calif. , Feb. 6, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Eric Bjerkholt, Executive Vice President, Corporate Development and Finance at Sunesis, will be presenting at the Leerink Swann 2013 Global Healthcare Conference on
01/10/13
Summary ToggleSunesis Announces Clinical Trial Updates and 2013 Milestones at the 31st Annual JP Morgan Healthcare Conference VALOR Enrollment Reaches 500 Patients; Enrollment Doubles in LI-1 Trial SOUTH SAN FRANCISCO, Calif., Jan. 10, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer of Sunesis, provided a corporate update, including a
01/02/13
Summary ToggleSunesis to Present at the J.P. Morgan Healthcare Conference SOUTH SAN FRANCISCO, Calif. , Jan. 2, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher , Chief Executive Officer of Sunesis, will be presenting at the J.P. Morgan Healthcare Conference on Thursday, January 10, 2013 at 12:00 PM Pacific Time at
11/20/12
Summary ToggleSunesis to Present at the Piper Jaffray 24th Annual Healthcare Conference SOUTH SAN FRANCISCO, Calif. , Nov. 20, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher , Chief Executive Officer of Sunesis, will be presenting at the Piper Jaffray 24 th Annual Healthcare Conference on Tuesday, November 27, 2012 at 11:00 AM
11/08/12
Summary ToggleSunesis Pharmaceuticals Reports Third Quarter 2012 Financial Results and Recent Highlights Sunesis to Host Conference Call Today at 11:00AM Eastern Time SOUTH SAN FRANCISCO, Calif., Nov. 8, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the quarter ended September 30, 2012 . Net loss for the three and nine months ended September
11/07/12
Summary ToggleSunesis to Present at the Lazard Capital Markets 9th Annual Healthcare Conference SOUTH SAN FRANCISCO, Calif. , Nov. 7, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher , Chief Executive Officer of Sunesis, will be presenting at the Lazard Capital Markets 9th Annual Healthcare Conference on Tuesday, November 13, 2012 at
11/01/12
Summary ToggleSunesis to Host Conference Call on November 8th to Discuss Third Quarter Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif. , Nov. 1, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Thursday, November 8th, 2012 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the third quarter ended
10/02/12
Summary ToggleSunesis Pharmaceuticals Announces Management Promotions SOUTH SAN FRANCISCO, Calif., Oct. 2, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced two management promotions, effective October 1, 2012 . Deborah A. Thomas, Ph.D., has been promoted to Vice President, Regulatory Affairs and Gene C.
09/27/12
Summary ToggleSunesis to Host Analyst & Institutional Investor Meeting on October 4, 2012 SOUTH SAN FRANCISCO, Calif. , Sept. 27, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the Company will host an analyst and institutional investor meeting on Thursday, October 4, 2012 , from 5:00 to 6:30 PM Eastern Time in New York City .
09/20/12
Summary ToggleSunesis Pharmaceuticals Announces Closing of $40 Million in Previously Announced Royalty and Debt Financings Company Funded Through VALOR Unblinding in 2014 SOUTH SAN FRANCISCO, Calif., Sept. 20, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the closing of two previously disclosed financings. Royalty Pharma has invested $25.0 million under its royalty arrangement
09/11/12
Summary ToggleSunesis Pharmaceuticals to Implement One-Time Sample Size Increase to Phase 3 VALOR Trial in AML DSMB Recommends Increase Following Single, Pre-Planned Interim Efficacy and Safety Analysis of VALOR; Enrollment Completion Expected in 2013 DSMB Recommendation Triggers $25.0 Million Investment in Sunesis from Royalty Pharma Sunesis to Host Conference Call Today at 9:00 AM Eastern Time SOUTH SAN
08/27/12
Summary ToggleSunesis to Present at Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif. , Aug. 27, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the Company will present at two upcoming investor conferences. Eric Bjerkholt, Executive Vice President, Corporate Development and Finance at Sunesis will present at the
08/09/12
Summary ToggleSunesis Pharmaceuticals Reports Second Quarter 2012 Financial Results and Highlights Sunesis to Host Conference Call Today at 10:30AM Eastern Time SOUTH SAN FRANCISCO, Calif., Aug. 9, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the quarter ended June 30, 2012 . Net loss for the three and six months ended June 30, 2012
08/08/12
Summary ToggleSunesis to Present at the 2012 Wedbush PacGrow Lifesciences Management Access Conference SOUTH SAN FRANCISCO, Calif., Aug. 8, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer of Sunesis, will be presenting at the 2012 Wedbush PacGrow Lifesciences Management Access Conference on Wednesday, August 15, 2012
08/02/12
Summary ToggleSunesis to Host Conference Call on August 9th to Discuss Second Quarter Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif. , Aug. 2, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Thursday, August 9th, 2012 at 10:30 a.m. Eastern Time to discuss corporate updates and financial results for the second quarter ended
07/24/12
Summary ToggleVosaroxin Review Published in Expert Opinion on Investigational Drugs SOUTH SAN FRANCISCO, Calif. , July 24, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the publication of a peer-reviewed paper in the August 2012 issue of Expert Opinion on Investigational Drugs (Volume 21, Number 8) featuring vosaroxin, the Company's lead
06/27/12
Summary ToggleSunesis Pharmaceuticals Receives $1.5 Million Milestone Payment From Biogen Idec Related to Kinase Inhibitor Program SOUTH SAN FRANCISCO, Calif. , June 27, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it has received a $1.5 million milestone payment from Biogen Idec (Nasdaq:BIIB) for the advancement of pre-clinical work under its 2011 amended and restated multi-kinase
06/14/12
Summary ToggleData and Safety Monitoring Board Recommends Continuation of Sunesis Pharmaceuticals' VALOR Trial Based on Periodic Safety Review Company Remains on Track for Interim Analysis in September 2012 SOUTH SAN FRANCISCO, Calif. , June 14, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the independent Data and Safety Monitoring Board (DSMB) for the VALOR trial has completed a planned
05/15/12
Summary ToggleSunesis Pharmaceuticals Reports First Quarter 2012 Financial Results and Highlights Sunesis to Host Conference Call Today at 11AM Eastern Time SOUTH SAN FRANCISCO, Calif. , May 15, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the quarter ended March 31, 2012 . Net loss for the three months ended March 31, 2012 was $13.9
05/08/12
Summary ToggleSunesis to Host Conference Call on May 15th to Discuss First Quarter Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif., May 8, 2012 (GlobeNewswire via COMTEX) --Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Tuesday, May 15th, 2012 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the first quarter ended
05/03/12
Summary ToggleSunesis Pharmaceuticals Receives European Orphan Drug Designation for Vosaroxin to Treat Acute Myeloid Leukemia SOUTH SAN FRANCISCO, Calif., May 3, 2012 (GlobeNewswire via COMTEX) --Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the European Commission has granted orphan drug designation to vosaroxin, the Company's lead development candidate, for the treatment of acute myeloid leukemia
04/13/12
Summary ToggleSunesis to Present at the 19th Annual Future Leaders in the Biotech Industry Conference SOUTH SAN FRANCISCO, Calif., Apr 13, 2012 (GlobeNewswire via COMTEX) --Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer of Sunesis, will be presenting at the 19th Annual Future Leaders in the Biotech Industry Conference on Friday, April 20,
03/29/12
Summary ToggleSunesis and Royalty Pharma Announce $25 Million Vosaroxin Royalty Agreement Design and Execution of VALOR Trial Enable Innovative Financing SOUTH SAN FRANCISCO, Calif. , March 29, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals (Nasdaq:SNSS) and Royalty Pharma today announced that Royalty Pharma has agreed to pay Sunesis $25 million , under certain circumstances related
03/14/12
Summary ToggleSunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2011 Financial Results and Highlights Sunesis to Host Conference Call Today at 10:30 AM Eastern Time SOUTH SAN FRANCISCO, Calif. , March 14, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the fourth quarter and year ended December 31, 2011 .
03/08/12
Summary ToggleSunesis to Host Conference Call on March 14th to Discuss Fourth Quarter and Full-Year 2011 Financial Results SOUTH SAN FRANCISCO, Calif. , March 8, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Wednesday March 14th, 2012 at 10:30 a.m. Eastern Time to discuss corporate updates and financial results for the fourth quarter and year
03/07/12
Summary ToggleSunesis to Present at the ROTH 24th Annual OC Growth Stock Conference SOUTH SAN FRANCISCO, Calif. , March 7, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Eric Bjerkholt, Executive Vice President, Corporate Development and Finance at Sunesis, will be presenting at the ROTH 24th Annual OC Growth Stock Conference on Tuesday,
02/29/12
Summary ToggleSunesis to Present at the Cowen and Company 32nd Annual Health Care Conference SOUTH SAN FRANCISCO, Calif. , Feb. 29, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher , Chief Executive Officer of Sunesis, will be presenting at the Cowen and Company 32nd Annual Health Care Conference on Tuesday, March 6, 2012 at 8:40 AM
02/21/12
Summary ToggleSunesis to Present at Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif. , Feb. 21, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the Company will present at two upcoming investor conferences. Daniel Swisher , Chief Executive Officer of Sunesis, will present at the 2012 Citi Healthcare Conference on
02/14/12
Summary ToggleSunesis Pharmaceuticals Announces Notice of Allowance for U.S. Patent Application Covering Vosaroxin Compositions SOUTH SAN FRANCISCO, Calif , Feb. 14, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 12/982,785 claiming certain compositions related to Sunesis' lead
02/07/12
Summary ToggleSunesis to Present at the 14th Annual BIO CEO & Investor Conference SOUTH SAN FRANCISCO, Calif. , Feb. 7, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher , Chief Executive Officer of Sunesis, will be presenting at the 14th Annual Biotechnology Industry Organization ( BIO) CEO & Investor Conference on Tuesday,
02/02/12
Summary ToggleSunesis Announces Appointment of Dr. Adam R. Craig as Chief Medical Officer Eric Bjerkholt Promoted to Executive Vice President, Corporate Development and Finance Image: Sunesis Pharmaceuticals, Inc. Logo Image: VALOR Logo Steven Ketchum , Senior Vice President, Research and Development, to Transition from Executive to Board Position SOUTH SAN FRANCISCO, Calif. , Feb.
12/12/11
Summary ToggleSunesis Announces Participation in Cardiff University Sponsored Phase 2/3 Trial Evaluating Vosaroxin in Newly Diagnosed Elderly AML and High-Risk MDS Patients SOUTH SAN FRANCISCO, Calif. , Dec. 12, 2011 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced participation in a Phase 2/3 randomized, controlled, multicenter trial evaluating novel treatment regimens against low dose cytarabine (LD Ara-C), a commonly used treatment of
12/09/11
Summary ToggleData and Safety Monitoring Board Recommends Continuation of Sunesis Pharmaceuticals' VALOR Trial Based on Periodic Safety Review Company Remains on Track for Interim Analysis in Mid-2012 SOUTH SAN FRANCISCO, Calif., Dec 9, 2011 (GlobeNewswire via COMTEX) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the independent Data and Safety Monitoring Board (DSMB) for the VALOR trial has completed a planned
12/06/11
Summary ToggleSunesis to Present at the Oppenheimer 22nd Annual Healthcare Conference SOUTH SAN FRANCISCO, Calif., Dec 6, 2011 (GlobeNewswire via COMTEX) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer of Sunesis, will be presenting at the Oppenheimer 22nd Annual Healthcare Conference on Tuesday, December 13, 2011 at 9:40
11/14/11
Summary ToggleSunesis Pharmaceuticals Reports Third Quarter 2011 Financial Results SOUTH SAN FRANCISCO, Calif. , Nov. 14, 2011 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the third quarter ended September 30, 2011 . Net loss for the three and nine months ended September 30, 2011 was $5.0 million and $11.4 million ,
11/08/11
Summary ToggleSunesis to Present at the Lazard Capital Markets 8th Annual Healthcare Conference SOUTH SAN FRANCISCO, Calif., Nov 8, 2011 (GlobeNewswire via COMTEX) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that
10/19/11
Summary ToggleSunesis Secures $25 Million Tranched Loan Facility First Tranche of $10 Million Funded at Close SOUTH SAN FRANCISCO, Calif., Oct 19, 2011 (GlobeNewswire via COMTEX) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it has entered into a $25 million tranched loan facility. Under the terms of the loan agreement, Sunesis received $10
10/11/11
Summary ToggleSunesis to Host Analyst & Institutional Investor Meeting on October 19, 2011 SOUTH SAN FRANCISCO, Calif., Oct 11, 2011 (GlobeNewswire via COMTEX) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the Company will host an analyst and institutional investor meeting on Wednesday, October 19, 2011, from 5:00 to 6:30 PM Eastern Time in New York City.
09/26/11
Summary ToggleSunesis Announces Initiation of Phase 1 Study of MLN2480 in Advanced Solid Tumors SOUTH SAN FRANCISCO, Calif., Sep 26, 2011 (GlobeNewswire via COMTEX) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the initiation of a Phase 1 clinical study of MLN2480, an oral, investigative drug selective for pan-Raf kinase inhibition, that is being studied in patients with
09/13/11
Summary ToggleSunesis to Present at the UBS Global Life Sciences Conference SOUTH SAN FRANCISCO, Calif., Sep 13, 2011 (GlobeNewswire via COMTEX) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that Eric
09/01/11
Summary ToggleSunesis to Present at Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Sep 1, 2011 (GlobeNewswire via COMTEX) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer of Sunesis, will present at two upcoming conferences: -- Stifel Nicolaus 2011 Healthcare Conference Friday, September 9th
08/11/11
Summary ToggleSunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results SOUTH SAN FRANCISCO, Calif., Aug 11, 2011 (GlobeNewswire via COMTEX) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the second quarter ended June 30, 2011. Net loss for the three and six months ended June 30, 2011 was $8.2 million and $6.4 million, respectively.
08/03/11
Summary ToggleSunesis Pharmaceuticals Issued Important U.S. Patent Covering Vosaroxin Use to Treat Leukemia SOUTH SAN FRANCISCO, Calif., Aug 3, 2011 (GlobeNewswire via COMTEX) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent No. 7,989,468 claiming methods of use for the Company's lead drug candidate, vosaroxin, at
07/20/11
Summary ToggleSunesis Announces Publication of Phase 1b Data of Vosaroxin in Relapsed or Refractory Acute Leukemia SOUTH SAN FRANCISCO, Calif., Jul 20, 2011 (GlobeNewswire via COMTEX) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the publication in Leukemia of data from a Phase 1b multi-center study of vosaroxin in relapsed or refractory leukemia.
06/06/11
Summary ToggleSunesis Announces Presentation of Adaptive Study Design for Vosaroxin Phase 3 VALOR Trial in AML at ASCO 2011 Annual Meeting Mid-2012 Interim Analysis Expected Sunesis to Host Conference Call Today at 9:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., June 6, 2011 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the presentation of the adaptive study design for its Phase 3 VALOR trial of
05/26/11
Summary ToggleSunesis to Host Conference Call on June 6th to Discuss Corporate Updates and VALOR Poster Presented at ASCO 2011 SOUTH SAN FRANCISCO, Calif., May 26, 2011 (GlobeNewswire via COMTEX) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Monday June 6, 2011 at 9:00 a.m. Eastern Time to discuss the progress of the VALOR trial, provide a general corporate update,
05/12/11
Summary ToggleSunesis Pharmaceuticals Reports First Quarter 2011 Financial Results SOUTH SAN FRANCISCO, Calif., May 12, 2011 (GlobeNewswire via COMTEX) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the quarter ended March 31, 2011. Net income for the three months ended March 31, 2011 was $1.8 million.
05/05/11
Summary ToggleSunesis Announces Publication of Nonclinical Data Demonstrating Activity of Vosaroxin Alone and in Combination With Cytarabine in Patients' Acute Myeloid Leukemia Blasts Vosaroxin Activity Retained in Absence of Functional p53, a Key Tumor Suppressing Protein That Confers Resistance to Chemotherapy SOUTH SAN FRANCISCO, Calif., May 5, 2011 (GlobeNewswire via COMTEX) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the publication of new nonclinical
04/05/11
Summary ToggleMillennium Pharmaceuticals and Sunesis Pharmaceuticals Announce Collaboration for Kinase Inhibitors in Oncology Sunesis Receives a $4M Payment Sunesis to Host Conference Call Today, April 5th at 10:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., and CAMBRIDGE, Mass., April 5, 2011 (GLOBE NEWSWIRE) -- Millennium: The Takeda Oncology Company and Sunesis Pharmaceuticals, Inc.
03/30/11
Summary ToggleSunesis to Present at the 10th Annual Needham Healthcare Conference SOUTH SAN FRANCISCO, Calif., Mar 30, 2011 (GlobeNewswire via COMTEX) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that
03/29/11
Summary ToggleSunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results SOUTH SAN FRANCISCO, Calif., Mar 29, 2011 (GlobeNewswire via COMTEX) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the fourth quarter and year ended December 31, 2010. Net loss for the three months and year ended December 31, 2010 was $10.1 million and $24.6
03/10/11
Summary ToggleSunesis Issued Important European Patent Covering Vosaroxin Clinical Formulation SOUTH SAN FRANCISCO, Calif., Mar 10, 2011 (GlobeNewswire via COMTEX) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSSD) today announced that the European Patent Office (EPO) has granted European Patent No. 1725233, claiming the Company's pharmaceutical compositions of lead drug candidate vosaroxin.
03/09/11
Summary ToggleSunesis to Present at ROTH 23rd Annual OC Growth Stock Conference SOUTH SAN FRANCISCO, Calif., Mar 9, 2011 (GlobeNewswire via COMTEX) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSSD) a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that
03/03/11
Summary ToggleSunesis Pharmaceuticals Regains NASDAQ Compliance SOUTH SAN FRANCISCO, Calif., Mar 3, 2011 (GlobeNewswire via COMTEX) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSSD) today announced that it has received notification from The NASDAQ Stock Market that it has regained compliance with the minimum $1.00 per share bid price requirement.
03/01/11
Summary ToggleSunesis to Present at Cowen and Company 31st Annual Health Care Conference SOUTH SAN FRANCISCO, Calif., Mar 1, 2011 (GlobeNewswire via COMTEX) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSSD), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that
02/24/11
Summary ToggleSunesis to Join Panel Discussion at the RBC Capital Markets' Healthcare Conference SOUTH SAN FRANCISCO, Calif., Feb 24, 2011 (GlobeNewswire via COMTEX) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSSD) a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that
02/23/11
Summary ToggleSunesis Receives FDA Fast Track Designation for Vosaroxin in AML SOUTH SAN FRANCISCO, Calif., Feb 23, 2011 (GlobeNewswire via COMTEX) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSSD) today announced that vosaroxin, the Company's lead drug candidate, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the potential treatment
02/14/11
Summary ToggleSunesis Announces 1-for-6 Reverse Stock Split Company Is Well Capitalized and Positioned for the Future SOUTH SAN FRANCISCO, CA, Feb 14, 2011 (MARKETWIRE via COMTEX) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a
02/08/11
Summary ToggleSunesis to Present at the 13th Annual BIO CEO & Investor Conference SOUTH SAN FRANCISCO, Calif., (February 8, 2011) - Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that Daniel Swisher, Chief
12/21/10
Summary ToggleSunesis Launches Phase 3 VALOR Trial of Vosaroxin in AML Randomized Trial Designed to Detect Significant Overall Survival Benefit SOUTH SAN FRANCISCO, CA, Dec 21, 2010 (MARKETWIRE via COMTEX) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that the first patient has been randomized and dosed with blinded study treatment in its pivotal
11/15/10
Summary ToggleSunesis Issued Important U.S. Patent Covering Vosaroxin Clinical Formulation SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 11/15/10 -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 7,829,577, claiming the Company's pharmaceutical compositions of lead drug candidate vosaroxin.
11/11/10
Summary ToggleSunesis Pharmaceuticals to Present at Lazard Capital Markets Annual Healthcare Conference SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 11/11/10 -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that Daniel Swisher ,
11/10/10
Summary ToggleSunesis Announces Positive Phase 2 Data for Vosaroxin in AML SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 11/10/10 -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced updated data from Phase 2 clinical trials of the Company's lead drug candidate, vosaroxin, in combination with cytarabine, a widely used chemotherapy, in relapsed/refractory acute
11/02/10
Summary ToggleSunesis Awarded $244,000 Grant Under the U.S. Qualified Therapeutic Discovery Project Program SOUTH SAN FRANCISCO, CA, Nov 02, 2010 (MARKETWIRE via COMTEX News Network) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) announced today that it has been awarded $244,000 under the IRS Qualifying Therapeutic Discovery Project (QTDP) program, which was created by Congress as part of the Patient
10/28/10
Summary ToggleSunesis Pharmaceuticals Reports Third Quarter 2010 Financial Results SOUTH SAN FRANCISCO, CA, Oct 28, 2010 (MARKETWIRE via COMTEX News Network) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today reported financial results for the third quarter ended September 30, 2010. Net loss was $5.1 million for the third quarter of 2010 and $14.5 million for the nine months
10/01/10
Summary ToggleSunesis Prices $15.5 Million Offering SOUTH SAN FRANCISCO, CA, Oct 01, 2010 (MARKETWIRE via COMTEX News Network) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) announced today the pricing of an underwritten offering of approximately 44.1 million units, each consisting of one share of its common stock and a warrant to purchase 0.5 of a
09/29/10
Summary ToggleSunesis Granted 180-Day Extension by NASDAQ to Regain Compliance With Minimum Bid Price Rule SOUTH SAN FRANCISCO, CA, Sep 29, 2010 (MARKETWIRE via COMTEX News Network) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) announced today that it received a letter, dated September 28, 2010, from The NASDAQ Stock Market notifying Sunesis that it has been granted an additional 180-day compliance
09/14/10
Summary ToggleSunesis to Present at the UBS Global Life Sciences Conference SOUTH SAN FRANCISCO, CA, Sep 14, 2010 (MARKETWIRE via COMTEX News Network) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced
08/12/10
Summary ToggleSunesis Pharmaceuticals Reports Second Quarter 2010 Financial Results SOUTH SAN FRANCISCO, CA, Aug 12, 2010 (MARKETWIRE via COMTEX News Network) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today reported financial results for the second quarter ended June 30, 2010. Net loss was $4.8 million for the second quarter of 2010.
08/04/10
Summary ToggleSunesis Pharmaceuticals Appoints Steering Committee and Clinical Partners for Vosaroxin Pivotal Phase 3 Trial in AML SOUTH SAN FRANCISCO, CA, Aug 04, 2010 (MARKETWIRE via COMTEX News Network) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced the Steering Committee and other clinical trial partners for its pivotal Phase 3 trial of vosaroxin in acute myeloid leukemia (AML).
08/03/10
Summary ToggleSunesis Pharmaceuticals to Present at BMO Capital Markets 10th Annual Focus on Healthcare Investor Conference SOUTH SAN FRANCISCO, CA, Aug 03, 2010 (MARKETWIRE via COMTEX News Network) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced
07/15/10
Summary ToggleSunesis Issued European Patent Covering Voreloxin Combination SOUTH SAN FRANCISCO, CA, Jul 15, 2010 (MARKETWIRE via COMTEX News Network) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that the European Patent Office (EPO) has granted a European patent covering combinations of the Company's lead drug candidate, voreloxin, with cytarabine.
06/30/10
Summary ToggleSunesis Closes $28.5 Million Final Tranche of 2009 Private Placement SOUTH SAN FRANCISCO, CA, Jun 30, 2010 (MARKETWIRE via COMTEX News Network) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that, in a final closing under a securities purchase agreement entered into on March 31, 2009 with a group of accredited investors, Sunesis has sold $28.5
06/07/10
Summary ToggleSunesis Announces Data From Phase 2 Clinical Program of Voreloxin in Acute Myeloid Leukemia Support Phase 3 Trial in Relapsed or Refractory Patients Updated, Positive Phase 2 Data in AML and Ovarian Cancer Presented at the ASCO 2010 Annual Meeting; Sunesis to Host Conference Call Tuesday, June 8th at 9:00 AM Eastern Time SOUTH SAN FRANCISCO, CA, Jun 07, 2010 (MARKETWIRE via COMTEX News Network) -- Sunesis Pharmaceuticals, Inc.
06/03/10
Summary ToggleSunesis to Present at Upcoming Investor Conferences SOUTH SAN FRANCISCO, CA, Jun 03, 2010 (MARKETWIRE via COMTEX News Network) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced
06/02/10
Summary ToggleSunesis Completes Consultative Review Process With EMA for Voreloxin in AML SOUTH SAN FRANCISCO, CA, Jun 02, 2010 (MARKETWIRE via COMTEX News Network) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that it has received written, scientific advice from the European Medicines Agency (EMA) on the Company's proposed plans for further development of voreloxin in
05/24/10
Summary ToggleSunesis to Host Conference Call on June 8th to Discuss Voreloxin Data Presented at ASCO 2010 and Upcoming Phase 3 Trial in AML SOUTH SAN FRANCISCO, CA, May 24, 2010 (MARKETWIRE via COMTEX News Network) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that it will host a conference call on Tuesday, June 8, 2010 at 9:00 a.m. Eastern time to review the data from the Phase 2 clinical trials of voreloxin in acute
04/29/10
Summary ToggleSunesis Pharmaceuticals Reports First Quarter 2010 Financial Results SOUTH SAN FRANCISCO, CA, Apr 29, 2010 (MARKETWIRE via COMTEX News Network) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today reported financial results for the first quarter ended March 31, 2010. Net loss was $4.6 million for the first quarter of 2010.
04/19/10
Summary ToggleAbstracts Highlighting Sunesis' Phase 2 Voreloxin Data Accepted for Presentation at 2010 ASCO Meeting SOUTH SAN FRANCISCO, CA, Apr 19, 2010 (MARKETWIRE via COMTEX News Network) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that data from three Phase 2 clinical trials of voreloxin, the company's lead drug candidate, have been accepted for presentation at the 2010 American Society
04/01/10
Summary ToggleSunesis Pharmaceuticals Receives NASDAQ Notification SOUTH SAN FRANCISCO, CA, Apr 01, 2010 (MARKETWIRE via COMTEX News Network) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) reported today that it received a letter, dated March 31, 2010, from the Listing Qualifications Staff (the "Staff") of The NASDAQ Stock Market notifying Sunesis that it does
03/30/10
Summary ToggleSunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2009 Financial Results SOUTH SAN FRANCISCO, CA, Mar 30, 2010 (MARKETWIRE via COMTEX News Network) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today reported financial results for the fourth quarter and fiscal year ended December 31, 2009. Net loss was $4.0 million for the fourth quarter of 2009 and $40.2 million for
03/01/10
Summary ToggleSunesis to Present at Upcoming Healthcare Conferences SOUTH SAN FRANCISCO, CA, Mar 01, 2010 (MARKETWIRE via COMTEX News Network) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that the Company is schedule to participate in the following events in March: -- RBC Capital Markets 2010 Healthcare Conference Panel: "Cancer: Improving
02/25/10
Summary ToggleSunesis Poised for Phase 3 Trial of Voreloxin in Acute Myeloid Leukemia After Completing Formal End-of-Phase 2 Meetings With FDA Company on Track to Initiate Pivotal Study in Second Half of 2010 SOUTH SAN FRANCISCO, CA, Feb 25, 2010 (MARKETWIRE via COMTEX News Network) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that it has completed formal End-of-Phase 2 meetings with the U.S.
02/08/10
Summary ToggleSunesis Grants Carmot Therapeutics License to Its Drug Discovery Technology SOUTH SAN FRANCISCO, CA, Feb 08, 2010 (MARKETWIRE via COMTEX News Network) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that it has granted Carmot Therapeutics, Inc., a privately-held biotechnology company, an exclusive license to its proprietary Fragment-Based Lead Discovery
01/21/10
Summary ToggleSunesis Completes Enrollment of Voreloxin Phase 1b/2 Combination Trial in Acute Myeloid Leukemia SOUTH SAN FRANCISCO, CA, Jan 21, 2010 (MARKETWIRE via COMTEX News Network) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today reported that it has completed enrollment in its Phase 1b/2 clinical trial evaluating voreloxin, the company's lead compound, in combination with cytarabine, a widely
01/14/10
Summary ToggleSunesis Announces Publication of Nonclinical Voreloxin Data in Leukemias Studies Demonstrate Voreloxin Acts Synergistically With Cytarabine and Induces Bone Marrow Aplasia SOUTH SAN FRANCISCO, CA, Jan 14, 2010 (MARKETWIRE via COMTEX News Network) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced the publication of new nonclinical studies with the Company's
12/28/09
Summary ToggleSunesis Pharmaceuticals Regains NASDAQ Compliance SAN FRANCISCO, CA, Dec 28, 2009 (MARKETWIRE via COMTEX News Network) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that it has received notification from The NASDAQ Stock Market that it has regained compliance with the minimum $1.00 per share bid price requirement.
12/07/09
Summary ToggleSunesis Presents Positive Phase 2 Clinical Data of Voreloxin in Acute Myeloid Leukemia at the American Society of Hematology 2009 Annual Meeting Conference Call Scheduled for December 8 at 2:00 PM EST to Discuss ASH Data Presentations SOUTH SAN FRANCISCO, CA, Dec 07, 2009 (MARKETWIRE via COMTEX News Network) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced positive data from two Phase 2 clinical trials of the Company's lead
12/01/09
Summary ToggleSunesis to Host Conference Call on Tuesday, December 8th to Discuss New Phase 2 Voreloxin Data Presented at ASH SOUTH SAN FRANCISCO, CA, Dec 01, 2009 (MARKETWIRE via COMTEX News Network) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that the company will host a conference call on Tuesday, December 8, 2009 at 2:00 PM EST to discuss the new clinical data from its Phase 2 voreloxin program
11/18/09
Summary ToggleSunesis Reports Data From Nonclinical Studies of Voreloxin at AACR-EORTC-NCI Conference SOUTH SAN FRANCISCO, CA, Nov 18, 2009 (MARKETWIRE via COMTEX News Network) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today reported data from two nonclinical studies of voreloxin at the AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference, which is being held in Boston, MA from
11/16/09
Summary ToggleSunesis Reports Financial Results for the Third Quarter of 2009 Voreloxin Abstracts Accepted for Presentation at ASH SOUTH SAN FRANCISCO, CA, Nov 16, 2009 (MARKETWIRE via COMTEX News Network) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today reported financial results for the third quarter ended September 30, 2009.
11/12/09
Summary ToggleSunesis to Present at the Lazard Capital Markets 6th Annual Healthcare Conference SOUTH SAN FRANCISCO, CA, Nov 12, 2009 (MARKETWIRE via COMTEX News Network) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced
11/10/09
Summary ToggleSunesis to Present Nonclinical Voreloxin Combination Data at AACR-EORTC-NCI Conference SOUTH SAN FRANCISCO, Calif., Nov 10, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will present new data from nonclinical studies of voreloxin at the upcoming AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics
11/05/09
Summary ToggleSunesis' Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia SOUTH SAN FRANCISCO, Calif., Nov 05, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML).
11/02/09
Summary ToggleSunesis Pharmaceuticals Completes Second Tranche of Private Placement SOUTH SAN FRANCISCO, Calif., Nov 02, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the closing of a private placement of $5.0 million of units consisting of convertible preferred stock and common stock warrants on October 30,
10/30/09
Summary ToggleSunesis Completes Enrollment of Voreloxin REVEAL-1 Trial in Acute Myeloid Leukemia SOUTH SAN FRANCISCO, Calif., Oct 30, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported that it has completed enrollment in the REVEAL-1 (Response Evaluation of VorEloxin in AmL) trial, a Phase 2 dose regimen optimization trial of
09/18/09
Summary ToggleSunesis Pharmaceuticals Receives NASDAQ Notification SOUTH SAN FRANCISCO, Calif., Sept 18, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) reported today that it received a letter, dated September 16, 2009, from the Listing Qualifications Staff (the "Staff") of The NASDAQ Stock Market notifying
07/30/09
Summary ToggleSunesis Receives Approval for Listing on The NASDAQ Capital Market SOUTH SAN FRANCISCO, Calif., July 30, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers,
07/29/09
Summary ToggleSunesis Reports Financial Results for the Second Quarter 2009 SOUTH SAN FRANCISCO, Calif., July 29, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the second quarter ended June 30, 2009. Total revenue for the second quarter of 2009 was $3.5 million, with a net loss of
07/27/09
Summary ToggleSunesis Pharmaceuticals Appoints Helen S. Kim to Board of Directors SOUTH SAN FRANCISCO, Calif., July 27, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Helen S. Kim has been appointed to the company's Board of Directors, effective immediately. Ms.
07/13/09
Summary ToggleSunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec SOUTH SAN FRANCISCO, Calif., July 13, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers,
06/16/09
Summary ToggleSunesis to Present at the Jefferies 3rd Annual Healthcare Conference SOUTH SAN FRANCISCO, Calif., June 16, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers,
06/01/09
Summary ToggleSunesis Pharmaceuticals Presents Voreloxin Clinical Data at the American Society of Clinical Oncology 2009 Annual Meeting -- Conference Call Scheduled for Today, Monday June 1, at 1:00 PM ET to Discuss ASCO Data Presentations -- SOUTH SAN FRANCISCO, Calif., June 1, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), announced today new data from three ongoing clinical
05/26/09
Summary ToggleSunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia and Ovarian Cancer Will Be Presented at ASCO -- Conference Call Scheduled for Monday June 1 at 1:00 PM ET to Discuss ASCO Data Presentations -- SOUTH SAN FRANCISCO, Calif., May 26, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a biopharmaceutical company focused on the development and
05/18/09
Summary ToggleSunesis Pharmaceuticals Receives Extension From NASDAQ to Regain Listing Compliance SOUTH SAN FRANCISCO, Calif., May 18, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) announced today that on May 13, 2009, it received a letter from The NASDAQ Stock Market notifying Sunesis that it had been granted an extension of time to regain
05/06/09
Summary ToggleSunesis Reports Financial Results for the First Quarter 2009 SOUTH SAN FRANCISCO, Calif., May 6, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the first quarter ended March 31, 2009. Total revenue for the first quarter of 2009 was $0.2 million, with a net loss of $8.4
04/17/09
Summary ToggleSunesis Pharmaceuticals Receives NASDAQ Notification SOUTH SAN FRANCISCO, Calif., April 17, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) reported today that it received a letter, dated April 14, 2009, from the Listing Qualifications Department of The NASDAQ Stock Market notifying the Company that
04/01/09
Summary ToggleSunesis Pharmaceuticals Announces Up To $43.5 Million Financing SOUTH SAN FRANCISCO, Calif., April 1, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the execution of a securities purchase agreement with accredited investors providing for a private placement of up to $43.5 million in a tranched
04/01/09
Summary ToggleSunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results -- Conference Call Scheduled for Today at 5:00 p.m. EDT - SOUTH SAN FRANCISCO, Calif., April 1, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the fourth quarter and fiscal year ended December 31, 2008.
03/09/09
Summary ToggleSunesis Pharmaceuticals Announces the Sale of its LFA-1 Inhibitor Program to SARcode Corporation SOUTH SAN FRANCISCO, Calif., March 9, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it has sold to SARcode its intellectual property and other assets in its LFA-1 inhibitor program previously licensed to SARcode for a total
02/04/09
Summary ToggleSunesis to Present at the 11th Annual BIO CEO & Investor Conference SOUTH SAN FRANCISCO, Calif., Feb 04, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers,
01/12/09
Summary ToggleSunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin SOUTH SAN FRANCISCO, Calif., Jan 12, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today provided a clinical update on voreloxin, its novel investigational drug candidate currently being developed in Phase 2 trials for acute myeloid leukemia
12/07/08
Summary ToggleSunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology SAN FRANCISCO, Dec 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- --Complete Remissions Achieved with Voreloxin in Poor Risk Frontline Elderly AML and in Combination with Cytarabine in Relapsed/Refractory AML- --Conference Call Scheduled for Tuesday, December 9 at 11:00 am ET to Discuss
12/01/08
Summary ToggleSunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH SOUTH SAN FRANCISCO, Calif., Dec 01, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- -- Conference Call Scheduled for Tuesday, December 9 at 11:00 am ET to Discuss Phase 2 Study Results in AML -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a biopharmaceutical company focused on the
11/25/08
Summary ToggleSunesis to Present at Upcoming Conferences SOUTH SAN FRANCISCO, Calif., Nov 25, 2008 /PRNewswire via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today
11/06/08
Summary ToggleSunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium - Voreloxin Demonstrates Promising Clinical Activity in Patients with Difficult-to-Treat Cancers - SOUTH SAN FRANCISCO, Calif., Nov 06, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) presented data from three clinical trials of the company's lead
11/04/08
Summary ToggleSunesis Reports Financial Results for the Third Quarter 2008 - Conference Call Scheduled for Today at 11:00 a.m. EST - SOUTH SAN FRANCISCO, Calif., Nov 04, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the third quarter ending September 30, 2008.
11/03/08
Summary ToggleSunesis to Present at Upcoming Conferences SOUTH SAN FRANCISCO, Calif., Nov 03, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers,
10/28/08
Summary ToggleSunesis Pharmaceuticals Announces Third Quarter Teleconference and Webcast on November 4, 2008 SOUTH SAN FRANCISCO, Calif., Oct 28, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics, today announced that management will webcast a
10/27/08
Summary ToggleSunesis Announces Updated Clinical Data of Voreloxin in Platinum-Resistant Ovarian Cancer - Preliminary Data from SNS-314 Phase 1 Clinical Trial Also Presented at EORTC - SOUTH SAN FRANCISCO, Calif., Oct 27, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced a presentation of updated interim results from an ongoing Phase 2
10/21/08
Summary ToggleSunesis Announces Multiple Clinical Data Presentations SOUTH SAN FRANCISCO, Calif., Oct 21, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced upcoming data and
09/05/08
Summary ToggleSARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases SOUTH SAN FRANCISCO, Calif., Sept 05, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- SARcode Corporation, a private company focused on small molecule LFA-1 inhibitors to treat inflammatory diseases, and Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced SARcode's initiation of a
08/07/08
Summary ToggleSunesis Pharmaceuticals Reports Financial Results for the Second Quarter 2008 SOUTH SAN FRANCISCO, Calif., Aug 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today reported financial results for
07/29/08
Summary ToggleSunesis Pharmaceuticals to Report Financial Results for the Second Quarter on August 7, 2008 SOUTH SAN FRANCISCO, Calif., July 29, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of new oncology therapeutics, today announced that management will
07/03/08
Summary ToggleSunesis Pharmaceuticals to Present at the Collins Stewart Fourth Annual Growth Conference SOUTH SAN FRANCISCO, Calif., July 3, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Daniel Swisher, Sunesis' Chief Executive Officer and President, will provide a corporate overview at the upcoming Collins Stewart Fourth
06/19/08
Summary ToggleSunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference SOUTH SAN FRANCISCO, Calif., June 19, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Eric Bjerkholt, Sunesis' Senior Vice President, Corporate Development and Finance, will provide a corporate update at the upcoming Jefferies
06/16/08
Summary ToggleSunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association Data from Phase 1 Single Agent and Phase 1b Combination Clinical Trials Demonstrate Voreloxin's Anti-Leukemic Activity SOUTH SAN FRANCISCO, Calif., June 16, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) presented data Saturday from two clinical
06/03/08
Summary ToggleSunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595) Development Leadership Team in Place to Advance Voreloxin to Late-Stage Trials Strategic Realignment Includes Workforce Reduction to Streamline Operations SOUTH SAN FRANCISCO, Calif., June 3, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc.
06/03/08
Summary ToggleSunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595) SOUTH SAN FRANCISCO, Calif., June 3, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the expansion of its late-stage development leadership team with the appointment of industry veterans Steven B.
05/31/08
Summary ToggleSunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting Positive Interim Safety and Efficacy Data Reported Trial Enrollment Advancing Ahead of Schedule SOUTH SAN FRANCISCO, Calif., May 31, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today presented an update of interim data from the company's
05/28/08
Summary ToggleSunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress SOUTH SAN FRANCISCO, Calif., May 28, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) will present data from ongoing clinical trials of voreloxin (formerly SNS-595) at two major upcoming oncology conferences.
05/21/08
Summary ToggleSunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia SOUTH SAN FRANCISCO, Calif., May 21, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the initiation of the REVEAL-1 (Response Evaluation of Voreloxin in Elderly AML) Phase 2 clinical trial of voreloxin (also known as SNS-595), the
05/13/08
Summary ToggleSunesis Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., May 13, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Eric Bjerkholt, Sunesis' Senior Vice President, Corporate Development and Finance, will provide a corporate update at the upcoming Rodman
05/08/08
Summary ToggleSunesis Pharmaceuticals Reports First Quarter 2008 Financial Results SOUTH SAN FRANCISCO, Calif., May 8, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule therapeutics, today reported
04/30/08
Summary ToggleSunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008 SOUTH SAN FRANCISCO, Calif., April 30, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule therapeutics, today announced
04/16/08
Summary ToggleSunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research SNS-032 Demonstrates Activity in Multiple Myeloma and Mantle Cell Lymphoma SOUTH SAN FRANCISCO, Calif., April 16, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported data from nonclinical studies of SNS-032 in multiple myeloma and
04/14/08
Summary ToggleSunesis Pharmaceuticals Presents Nonclinical Data on SNS-595 at the Annual Meeting of the American Association for Cancer Research Nonclinical Studies Demonstrate that SNS-595 Acts through a Dual Mechanism and May Evade Common Drug Resistance Mechanisms Research Supports Current Clinical Development of SNS-595 in AML and Ovarian Cancer and Potential in Additional Indications SOUTH SAN FRANCISCO, Calif., April 14, 2008
04/09/08
Summary ToggleSunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research SOUTH SAN FRANCISCO, Calif., April 9, 2008, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the company will present data on each of its clinical-stage anticancer compounds at the upcoming Annual Meeting of the American
03/13/08
Summary ToggleSunesis Pharmaceuticals to Present at Healthcare Investor Conferences in March SOUTH SAN FRANCISCO, Calif., March 13, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Daniel Swisher, Sunesis' Chief Executive Officer and President, will provide a corporate overview at two upcoming investor conferences in
03/11/08
Summary ToggleSunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results SOUTH SAN FRANCISCO, Calif., March 11, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule therapeutics, today reported
03/10/08
Summary ToggleSunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer SOUTH SAN FRANCISCO, Calif., March 10, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule therapeutics, today announced
03/05/08
Summary ToggleSunesis Pharmaceuticals to Report Fourth Quarter and Full-Year 2007 Financial Results on March 11, 2008 SOUTH SAN FRANCISCO, Calif., March 5, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company developing novel anticancer therapeutics, today announced that management will hold an investor conference call on
03/04/08
Summary ToggleSunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Women's Cancer SOUTH SAN FRANCISCO, Calif., March 4, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company developing novel anticancer therapeutics, will present data at the upcoming 39th Annual Meeting on Women's Cancer
02/20/08
Summary ToggleSunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration SOUTH SAN FRANCISCO, Calif., Feb 20, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it has earned a preclinical milestone payment from Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
02/05/08
Summary ToggleSunesis Pharmaceuticals to Present at the BIO CEO & Investor Conference SOUTH SAN FRANCISCO, Calif., Feb 05, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Daniel Swisher, Sunesis' Chief Executive Officer and President, will present a corporate update at the upcoming 10th Annual BIO CEO &
12/19/07
Summary ToggleSunesis Pharmaceuticals and the Multiple Myeloma Research Consortium Form Collaboration to Study SNS-032 in Multiple Myeloma SOUTH SAN FRANCISCO, Calif., Dec 19, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) and the Multiple Myeloma Research Consortium (MMRC) have entered into a collaboration to evaluate Sunesis' SNS-032 as a potential therapeutic for the treatment of
12/10/07
Summary ToggleSunesis Pharmaceuticals' SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology Conference Call Scheduled for 4:00 p.m. Eastern Time to Review Clinical Trial Results for SNS-595 and Non-clinical Data for SNS-032 Presented at the ASH Meeting ATLANTA, Dec 10, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc.
12/07/07
Summary ToggleSunesis Pharmaceuticals to Present at the RBC Capital Markets Healthcare Conference SOUTH SAN FRANCISCO, Calif., Dec 07, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Daniel Swisher, Sunesis' Chief Executive Officer and President, will participate in a panel discussion, "Novel Cancer Targets," at the 2007
12/03/07
Summary ToggleSunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development SOUTH SAN FRANCISCO, Calif., Dec 03, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics, today announced the
11/29/07
Summary ToggleSunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology Management and Third-Party Investigators to Conduct Conference Call on December 10, 2007 to Discuss SNS-595 Clinical Trial Results and SNS-032 Non-clinical Data SOUTH SAN FRANCISCO, Calif., Nov 29, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc.
11/01/07
Summary ToggleSunesis Pharmaceuticals Reports Third Quarter 2007 Financial Results SOUTH SAN FRANCISCO, Calif., Nov 01, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics, today reported
10/31/07
Summary ToggleSunesis Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference SOUTH SAN FRANCISCO, Calif., Oct 31, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Daniel N. Swisher, Sunesis' Chief Executive Officer and President, will present a company update at the Acumen BioFin Rodman & Renshaw
10/26/07
Summary ToggleSunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results SOUTH SAN FRANCISCO, Calif., Oct 26, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company developing novel anticancer therapeutics, today announced that management will hold an investor conference call on
10/23/07
Summary ToggleSunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference Criteria to Advance SNS-595 to Next Stage of Phase 2 Trial Achieved SOUTH SAN FRANCISCO, Calif., Oct 23, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- /ADVANCE FOR RELEASE AT 3:30 P.M. EDT, TODAY/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company
10/23/07
Summary ToggleSunesis Pharmaceuticals Hosts Conference Call to Discuss Preliminary SNS-595 Activity in its Ovarian Cancer Clinical Trial Being Reported at the AACR-NCI-EORTC International Conference SOUTH SAN FRANCISCO, Calif., Oct 23, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), today announced that management will host a conference call this afternoon at 3:30 p.m. Eastern Time/12:30 p.m. Pacific Time to review preliminary data from
10/17/07
Summary ToggleSunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics SOUTH SAN FRANCISCO, Calif., Oct 17, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company developing novel anticancer therapeutics, today announced that the company will present data at the AACR-NCI-EORTC
10/04/07
Summary ToggleSunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350 SOUTH SAN FRANCISCO, Calif., Oct 04, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the grant of employment inducement stock options awards in accordance with NASDAQ Marketplace Rule 4350 to two new non-executive employees.
09/12/07
Summary ToggleSunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314 SOUTH SAN FRANCISCO, Calif., Sept 12, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) announced today that patient dosing has commenced in clinical trials to evaluate two of the company's anti-cancer product candidates, SNS-595 and SNS-314.
08/28/07
Summary ToggleSunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs SOUTH SAN FRANCISCO, Calif., Aug 28, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it is reducing its workforce by approximately 25 percent, and implementing a revised operating plan that focuses its efforts on generating
08/02/07
Summary ToggleSunesis Pharmaceuticals Reports Second Quarter 2007 Financial Results SOUTH SAN FRANCISCO, Calif., Aug 02, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics, today reported
07/26/07
Summary ToggleSunesis Pharmaceuticals to Report Second Quarter 2007 Financial Results SOUTH SAN FRANCISCO, Calif., July 26, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company developing novel anticancer therapeutics, today announced that management will hold an investor conference call on
07/03/07
Summary ToggleSunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference SOUTH SAN FRANCISCO, Calif., July 3, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Eric Bjerkholt, Sunesis' Senior Vice President, Corporate Development and Finance, will present a company update at the C. E.
06/21/07
Summary ToggleSunesis Pharmaceuticals to Present at the Jefferies Healthcare Conference SOUTH SAN FRANCISCO, Calif., June 21, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Eric Bjerkholt, Senior Vice President, Corporate Development and Finance, will present a company update at the Jefferies Healthcare
06/11/07
Summary ToggleSunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association Interim Data from Phase 1 Clinical Trial of SNS-595 in Acute Leukemia Demonstrates Additional Clinical Activity SOUTH SAN FRANCISCO, Calif., June 11, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) presented positive data from clinical studies of
06/08/07
Summary ToggleSunesis Pharmaceuticals to Present at Needham Biotechnology & Medical Technology Conference SOUTH SAN FRANCISCO, Calif., June 8, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Daniel N. Swisher, Sunesis' Chief Executive Officer and President, will present a company update at the 6th Annual Needham Biotechnology
06/05/07
Summary ToggleSunesis Pharmaceuticals Receives Preclinical Milestone Payment from SARcode Corporation SOUTH SAN FRANCISCO, Calif., June 5, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it has earned a milestone payment from SARcode Corporation for progress made by SARcode in the preclinical development of a novel LFA-1
06/01/07
Summary ToggleSunesis Pharmaceuticals to Present Data at the 12th Congress of the European Hematology Association SOUTH SAN FRANCISCO, Calif., June 1, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the company will present data from ongoing clinical studies of SNS-595 and SNS-032 at the 12th Congress of the European Hematology
05/24/07
Summary ToggleSunesis Pharmaceuticals Announces Pricing of Public Offering of Common Stock SOUTH SAN FRANCISCO, Calif., May 24, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the pricing of its public offering of 4,750,000 shares of common stock at a price of $4.43 per share.
05/08/07
Summary ToggleSunesis Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference SOUTH SAN FRANCISCO, Calif., May 8, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Daniel N. Swisher, Jr., Chief Executive Officer and President, will present a company update at the Rodman & Renshaw 4th Annual Global
05/04/07
Summary ToggleSunesis Pharmaceuticals Reports First Quarter 2007 Financial Results Date of Annual Shareholders' Meeting Set SOUTH SAN FRANCISCO, Calif., May 4, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small
05/02/07
Summary ToggleSunesis Pharmaceuticals Announces Preclinical Milestone Payment in BACE Collaboration with Merck SOUTH SAN FRANCISCO, Calif., May 2, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it has earned a $1 million payment from Merck & Co., Inc. for meeting a preclinical milestone in the companies' collaboration to develop
04/27/07
Summary ToggleSunesis Pharmaceuticals to Report First Quarter 2007 Financial Results SOUTH SAN FRANCISCO, Calif., April 27, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company developing novel anticancer therapeutics, today announced that management will hold an investor conference call on
04/17/07
Summary ToggleSunesis Pharmaceuticals Appoints Valerie L. Pierce Senior Vice President, General Counsel and Corporate Secretary SOUTH SAN FRANCISCO, Calif., April 17, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the appointment of Valerie L. Pierce to Senior Vice President, General Counsel and Corporate Secretary. Ms.
04/16/07
Summary ToggleSunesis Presents Data Supporting SNS-032's Potential Anticancer Activity in Multiple Myeloma at the American Association for Cancer Research Meeting Results from Non-clinical Studies Confirm Mechanism of Action and Provide Guidance for Dosing SOUTH SAN FRANCISCO, April 16, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) presented non-clinical data demonstrating SNS-032's apoptotic activity in
04/13/07
Summary ToggleSunesis Pharmaceuticals to Present Data at the Annual Meeting of the American Association for Cancer Research SOUTH SAN FRANCISCO, Calif., April 13, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the company will present data at the Annual Meeting of the American Association for Cancer Research (AACR) being held April 14-18, 2007 in
03/23/07
Summary ToggleSunesis Pharmaceuticals to Present at the Future Leaders in the Biotech Industry Conference SOUTH SAN FRANCISCO, Calif., March 23, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Daniel N. Swisher, Jr., Chief Executive Officer and President, will provide a corporate presentation at the 14th Annual Future Leaders in
03/20/07
Summary ToggleSunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility Research from Non-clinical Studies Presented at the Targeted Anticancer Therapies (TAT 2007) and the Keystone Symposia Molecular Targets for Cancer Meetings Support Phase 1 Trial Design SOUTH SAN FRANCISCO, Calif., March 20, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis
03/13/07
Summary ToggleSunesis Pharmaceuticals to Present at the Lehman Brothers 10th Annual Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., March 13, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that James W. Young, Ph.D., Executive Chairman, will provide a corporate presentation at the Lehman Brothers Tenth Annual Global Healthcare
03/09/07
Summary ToggleSunesis Pharmaceuticals Reports Fourth Quarter and Full Year 2006 Financial Results SOUTH SAN FRANCISCO, Calif., March 9, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule therapeutics, today reported
03/07/07
Summary ToggleSunesis Pharmaceuticals to Present at the Cowen and Company 27th Annual Health Care Conference SOUTH SAN FRANCISCO, Calif., March 7, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Daniel N. Swisher, Jr., Chief Executive Officer and President, will provide a corporate presentation at the Cowen and Company 27th Annual
03/06/07
Summary ToggleSunesis Initiates Phase 1 Clinical Trial of SNS-032 in Patients With B-cell Malignancies Clinical Trial Based on Preclinical Evidence of SNS-032's Activity to Target Hematologic Cancers SOUTH SAN FRANCISCO, Calif., March 6, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) announced today the dosing of the first patient in a Phase 1
03/02/07
Summary ToggleSunesis Pharmaceuticals to Report Financial Results for the Fourth Quarter and Fiscal Year 2006 SOUTH SAN FRANCISCO, Calif., March 2, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company developing novel anticancer therapeutics, today announced that management will hold an investor conference call on
03/01/07
Summary ToggleSunesis Pharmaceuticals Files Investigational New Drug Application for Novel Aurora Kinase Inhibitor, SNS-314 SOUTH SAN FRANCISCO, Calif., March 1, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), announced today that the company has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for SNS-314, an
01/29/07
Summary ToggleSunesis Pharmaceuticals Reports Positive Initial Results From Phase 2 Small Cell Lung Cancer Trial With SNS-595 Company to Review Topline Data From First Stage of Phase 2 Lung Cancer Trials in Conference Call Today SOUTH SAN FRANCISCO, Calif., Jan 29, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the company will advance the
01/04/07
Summary ToggleSunesis Out-Licenses LFA-1 Program to SARcode Corporation Sunesis Receives License Payment and Convertible Note SOUTH SAN FRANCISCO, Calif., Jan 04, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) announced today the out-license of the company's LFA-1 inhibitor program to SARcode Corporation, a
01/03/07
Summary ToggleSunesis Pharmaceuticals to Present at the 25th Annual JPMorgan Healthcare Conference SOUTH SAN FRANCISCO, Calif., Jan 03, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Daniel N. Swisher, Jr., Chief Executive Officer and President, will provide a corporate presentation at the 25th Annual JPMorgan Healthcare
12/21/06
Summary ToggleSunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of SNS-595 in Ovarian Cancer SOUTH SAN FRANCISCO, Calif., Dec 21, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that dosing has begun in a Phase 2 clinical trial of SNS-595, the company's lead anti-cancer therapeutic, in patients with ovarian cancer.
12/10/06
Summary TogglePreliminary Results from Sunesis Pharmaceuticals’ Phase 1 Trial of SNS-595 in Patients with Advanced Leukemias Demonstrate Promising Clinical Activity Data Presented at ASH Annual Meeting Show SNS-595 is Well Tolerated and Decreases Leukemic Blast Cells among Heavily Pre-treated Patients South San Francisco, CA, December 10, 2006 – Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) presented data on its lead compound, SNS-595, from an ongoing Phase 1
12/04/06
Summary ToggleSunesis Pharmaceuticals to Present Data on SNS-595 at American Society for Hematology Meeting SOUTH SAN FRANCISCO, Calif., Dec 04, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the company will present data from clinical and preclinical studies of SNS-595 in advanced leukemias at the upcoming American Society for
11/21/06
Summary ToggleSunesis Pharmaceuticals to Present at the Lazard Capital Markets Life Sciences Conference SOUTH SAN FRANCISCO, Calif., Nov 21, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Daniel N. Swisher, Jr., Chief Executive Officer and President, and Eric Bjerkholt, Chief Financial Officer, will present a corporate update
11/15/06
Summary ToggleSunesis Pharmaceuticals Announces Filing of Universal Shelf Registration Statement SOUTH SAN FRANCISCO, Calif., Nov 15, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the filing of a $75 million universal shelf registration statement on Form S-3 with the Securities and Exchange Commission (SEC).
11/02/06
Summary ToggleSunesis Pharmaceuticals Reports Third Quarter 2006 Financial Results SOUTH SAN FRANCISCO, Calif., Nov 02, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics, today reported
11/01/06
Summary ToggleSunesis Pharmaceuticals to Present at the Cowen and Company Global Health Care Conference SOUTH SAN FRANCISCO, Calif., Nov 01, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Daniel N. Swisher, Jr., Chief Executive Officer and President, will present a corporate update at the Cowen and Company 7th Annual Global
10/31/06
Summary ToggleSunesis Pharmaceuticals to Present at the Rodman & Renshaw Healthcare Conference SOUTH SAN FRANCISCO, Calif., Oct 31, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that James W. Young, Ph.D., Executive Chairman, will present a corporate update at the Rodman & Renshaw 8th Annual Healthcare Conference on
10/30/06
Summary ToggleSunesis Pharmaceuticals to Report Third Quarter 2006 Financial Results November 2, 2006 SOUTH SAN FRANCISCO, Calif., Oct 30, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics, today announced that
10/24/06
Summary ToggleSunesis Pharmaceuticals to Present at the C.E. Unterberg, Towbin Life Sciences Conference SOUTH SAN FRANCISCO, Calif., Oct 24, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that James W. Young, Ph.D., Executive Chairman, will present a corporate update at the C.E. Unterberg, Towbin Life Sciences Conference on Monday,
09/26/06
Summary ToggleSunesis Pharmaceuticals Appoints William L. Schary, Ph.D., Vice President, Regulatory Affairs and Quality Assurance Robert McDowell, Ph.D., Promoted to Vice President, Research SOUTH SAN FRANCISCO, Calif., Sept 26, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the appointment of William L. Schary, Ph.D., to the position of Vice President,
09/07/06
Summary ToggleSunesis Pharmaceuticals to Present at the Bear Stearns 19th Annual Healthcare Conference SOUTH SAN FRANCISCO, Calif., Sept 07, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Daniel N. Swisher, Jr., Chief Executive Officer and President, will present a corporate update at the Bear Stearns 19th Annual Healthcare
08/10/06
Summary ToggleSunesis Pharmaceuticals Reports Second Quarter 2006 Financial Results SOUTH SAN FRANCISCO, Calif., Aug 10, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics, today reported
08/03/06
Summary ToggleSunesis Pharmaceuticals to Report Second Quarter 2006 Financial Results August 10, 2006 SOUTH SAN FRANCISCO, Calif., Aug 03, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics, today announced that
07/28/06
Summary ToggleSunesis Pharmaceuticals to Present at the Baird Equity Focus on Oncology Conference SOUTH SAN FRANCISCO, Calif., July 28, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Duncan Walker, Ph.D., Vice President, Discovery Biology, will present an update on the company's cancer drug development programs at the
07/06/06
Summary ToggleSunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference SOUTH SAN FRANCISCO, Calif., July 6, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Daniel N. Swisher, Jr., Chief Executive Officer and President, will present a company update at the C. E.
06/29/06
Summary ToggleSunesis Appoints Homer L. Pearce, Ph.D., and David C. Stump, M.D., to Board of Directors SOUTH SAN FRANCISCO, Calif., June 29, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Homer L. Pearce, Ph.D., and David C. Stump, M.D., have been appointed to the company's Board of Directors. Dr.
06/13/06
Summary ToggleSunesis Pharmaceuticals to Present at the Needham 5th Annual Biotechnology & Medical Technology Conference SOUTH SAN FRANCISCO, Calif., June 13, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Daniel N. Swisher, Jr., Chief Executive Officer and President, will present a company update at the Needham 5th Annual Biotechnology and
06/12/06
Summary ToggleSunesis Pharmaceuticals Announces Preclinical Milestone Payment in BACE Collaboration with Merck SOUTH SAN FRANCISCO, Calif., June 12, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it has earned a $4.25 million payment from Merck & Co., Inc. for meeting certain preclinical milestones in the companies' collaboration
06/08/06
Summary ToggleSunesis Pharmaceuticals to Present at Pacific Growth Equities 2006 Life Sciences Growth Conference SOUTH SAN FRANCISCO, Calif., June 8, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Jim Young, Executive Chairman, will present a company update at the Pacific Growth Equities 2006 Life Sciences Growth Conference.
06/05/06
Summary ToggleSunesis Pharmaceuticals Presents Clinical Data on SNS-595 at the American Society of Clinical Oncology Annual Meeting ATLANTA, June 5, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) presented promising clinical data at the 42nd Annual American Society of Clinical Oncology Meeting from two Phase I studies evaluating once-weekly and once-every-three-week dosing
05/31/06
Summary ToggleSunesis Pharmaceuticals to Present Clinical Data at the 2006 Annual Meeting of the American Society of Clinical Oncology SOUTH SAN FRANCISCO, Calif., May 31, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the company will present data from its Phase I clinical studies of SNS-595 during the upcoming 2006 Annual Meeting of the American Society of
05/10/06
Summary ToggleSunesis Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference SOUTH SAN FRANCISCO, Calif., May 10, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Daniel N. Swisher, Jr., Chief Executive Officer and President, will present a company update at the Rodman & Renshaw 3rd Annual Global
05/04/06
Summary ToggleSunesis Pharmaceuticals Reports First Quarter 2006 Financial Results Date of Annual Shareholders' Meeting Set SOUTH SAN FRANCISCO, Calif., May 4, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small
04/27/06
Summary ToggleSunesis Pharmaceuticals to Report First Quarter 2006 Financial Results May 4, 2006 SOUTH SAN FRANCISCO, Calif., April 28, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics, today announced
04/17/06
Summary ToggleSunesis Pharmaceuticals Enters Research and License Agreement With University of California, San Francisco SOUTH SAN FRANCISCO, Calif., April 7, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the company has entered into a research and license agreement with the University of California, San Francisco (UCSF).
04/04/06
Summary ToggleSunesis Presents Data on Anti-Cancer Compound SNS-032 at American Association for Cancer Research Meeting SNS-032 Demonstrated to Have Dual Activity, Targeting Both Proliferation and Apoptosis WASHINGTON, April 4, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) presented data at the Annual Meeting of the American Association for Cancer Research (AACR)
04/04/06
Summary ToggleSunesis Presents Results From Phase I Clinical and Preclinical Studies of SNS-595 at American Association for Cancer Research Meeting SNS-595 Was Well Tolerated With Promising Signs of Clinical Activity WASHINGTON, April 4, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) presented clinical and preclinical data on the company's lead compound, SNS-595 at the Annual Meeting of the
03/29/06
Summary ToggleSunesis Pharmaceuticals to Present Data on Clinical-Stage Product Candidates at the Annual Meeting of the American Association for Cancer Research SOUTH SAN FRANCISCO, Calif., March 29, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the company will present five posters during the upcoming Annual Meeting of the American Association for Cancer Research (AACR) being held
03/24/06
Summary ToggleSunesis Pharmaceuticals Reports Fourth Quarter and Full Year 2005 Financial Results SOUTH SAN FRANCISCO, Calif., March 24, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics, today reported
03/20/06
Summary ToggleSunesis Pharmaceuticals Initiates Phase II Clinical Trial of SNS-595 in Small Cell Lung Cancer SOUTH SAN FRANCISCO, Calif., March 20, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that patient treatment has commenced in a Phase II clinical trial of SNS-595, the company's lead anti-cancer therapeutic, in patients with small
03/17/06
Summary ToggleSunesis Pharmaceuticals Announces $45 Million Private Placement SOUTH SAN FRANCISCO, Calif., March 17, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics, today announced
03/17/06
Summary ToggleSunesis Pharmaceuticals to Report 2005 Financial Results on March 24, 2006 SOUTH SAN FRANCISCO, Calif., March 17, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics, today announced
03/08/06
Summary ToggleSunesis Pharmaceuticals to Present at Lehman Brothers Ninth Annual Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., March 8, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Daniel N. Swisher, Jr., President and Chief Executive Officer, will present a company update at the Lehman Brothers Ninth Annual Global
03/03/06
Summary ToggleSunesis Pharmaceuticals to Present at Cowen & Co. 26th Annual Health Care Conference SOUTH SAN FRANCISCO, Calif., March 3, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Daniel N. Swisher, Jr., President and Chief Executive Officer, will present a company update at the Cowen & Co.
02/10/06
Summary ToggleSunesis Pharmaceuticals to Present at BIO CEO and Investor Conference SOUTH SAN FRANCISCO, Calif., Feb 10, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Daniel N. Swisher, Jr., Chief Executive Officer and President, will present a company update at the 8th Annual BIO CEO and Investor
01/31/06
Summary ToggleSunesis Commences Phase I Clinical Trial of SNS-032 for Cancer SOUTH SAN FRANCISCO, California, January 31, 2006 -Sunesis Pharmaceuticals, Inc. announced today that patient treatment has commenced in a Phase I clinical trial of SNS-032. SNS-032 is a novel small molecule inhibitor of cyclin-dependent kinases (CDK) 2, 7 and 9.
01/04/06
Summary ToggleSunesis Pharmaceuticals Initiates Phase II Clinical Trial of SNS-595 in Non-Small Cell Lung Cancer SOUTH SAN FRANCISCO, Calif., Jan 04, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that patient treatment has commenced in a Phase II clinical trial of SNS-595, the company's lead anti-cancer therapeutic, in patients with
12/07/05
Summary ToggleSunesis Pharmaceuticals Receives Milestone Payment from Biogen Idec SOUTH SAN FRANCISCO, Calif., Dec 07, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics, has received a
11/17/05
Summary ToggleSunesis Pharmaceuticals Presents Promising Results of Phase I Clinical Trial of SNS-595 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics PHILADELPHIA, Nov 17, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics, announced positive results from the
11/15/05
Summary ToggleSunesis Pharmaceuticals Initiates Leukemia Clinical Trial SOUTH SAN FRANCISCO, Calif., Nov 15, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that patient treatment has commenced in a Phase I clinical trial of SNS-595, the company's lead anti- cancer small molecule drug, in patients with
11/14/05
Summary ToggleSunesis Pharmaceuticals Reports Third Quarter 2005 Financial Results SOUTH SAN FRANCISCO, Calif., Nov 14, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics, today reported
11/08/05
Summary ToggleSunesis Pharmaceuticals to Report Third Quarter Financial Results on November 14, 2005 SOUTH SAN FRANCISCO, Calif., Nov 08, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics, today announced that
11/07/05
Summary ToggleSunesis Pharmaceuticals to Present Data on SNS-595 and Kinase Inhibitor Programs at the Upcoming AACR-NCI-EORTC International Conference SOUTH SAN FRANCISCO, Calif., Nov 07, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will present scientific and clinical updates through two poster sessions and one oral presentation at the AACR-NCI-EORTC Molecular Targets
11/03/05
Summary ToggleSunesis Pharmaceuticals to Present at SG Cowen & Co. 6th Annual Health Care Conference SOUTH SAN FRANCISCO, Calif., Nov 03, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Eric Bjerkholt, Senior Vice President and Chief Financial Officer, will present a company update at the SG Cowen & Co.
10/21/05
Summary ToggleSunesis Pharmaceuticals to Present at C.E. Unterberg, Towbin Life Sciences Conference SOUTH SAN FRANCISCO, Calif., Oct 21, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) announced today that Daniel N. Swisher, Jr., Chief Executive Officer and President, is scheduled to present a corporate update at the upcoming C.E.
09/27/05
Summary ToggleSunesis Pharmaceuticals Sets Price for Initial Public Offering South San Francisco, CA, September 27, 2005 – Sunesis Pharmaceuticals, Inc. today announced the initial public offering of 6,000,000 shares of its common stock at a price of $7.00 per share. Shares of Sunesis' common stock will be traded on the Nasdaq National Market under the trading symbol
08/29/05
Summary ToggleSunesis Pharmaceuticals Selects Development Candidate for Aurora Kinase Program South San Francisco, CA, August 29, 2005 - Sunesis Pharmaceuticals, Inc. today announced that the company has selected an Aurora kinase development candidate, designated SNS-314, for IND-enabling preclinical development. SNS-314 is a small molecule kinase inhibitor that has shown promising
06/27/05
Summary ToggleSunesis Founder, James A. Wells, Ph.D., Joins UCSF Faculty South San Francisco, CA, June 27, 2005 – Sunesis Pharmaceuticals, Inc. today announced that James A. Wells, Ph.D., Sunesis founder, President and Chief Scientific Officer, is joining the faculty of the University of California, San Francisco (UCSF). Dr.
06/16/05
Summary ToggleSunesis Appoints Matthew Fust to Board of Directors South San Francisco, CA, June 16, 2005 – Sunesis Pharmaceuticals, Inc. today announced that Matthew Fust, Senior Vice President and Chief Financial Officer of Jazz Pharmaceuticals, will be joining Sunesis’ Board of Directors. This appointment, effective immediately, brings the total number of
05/26/05
Summary ToggleSunesis Promotes Gradon Knotts to Vice President, Business Development South San Francisco, CA, May 26, 2005 – Sunesis Pharmaceuticals, Inc. today announced the promotion of Gradon Knotts to the newly created position of Vice President, Business Development. Mr. Knotts joined Sunesis in May 2003 as Senior Director, Business Development, bringing more than fifteen
04/28/05
Summary ToggleSunesis to Acquire Clinical-Stage, Anti-Cancer Compound from Bristol-Myers Squibb SNS-032 Expands Sunesis' Pipeline of Novel Anti-Cancer Therapeutics South San Francisco, California, April 28, 2005 – Sunesis Pharmaceuticals, Inc. announced today that it has obtained worldwide development and commercialization rights to BMS-387032 (now SNS-032), a targeted small molecule
04/18/05
Summary ToggleSunesis Presents Data on Anti-Cancer Therapy, SNS-595 at American Association of Cancer Research Meeting SNS-595 Demonstrates Unique Mechanism of Action and Consistent In Vitro and In Vivo Activity South San Francisco, California, April 18, 2005 – Sunesis Pharmaceuticals, Inc. today presented data on the company’s lead anti-cancer therapy, SNS-595, that provide new insights into the drug’s mechanism
04/15/05
Summary ToggleSunesis to Present Data on SNS-595 at American Association of Cancer Research Meeting South San Francisco, California, April 15, 2005 – Sunesis Pharmaceuticals, Inc. today announced that three posters addressing in vitro and in vivo studies of the company’s lead anti-cancer therapy, SNS-595, will be presented at the 96th American Association of Cancer Research (AACR) annual meeting
02/28/05
Summary ToggleSunesis Presents Promising In Vivo Data on Aurora Kinase Program Compound Discovered at Sunesis Shows Robust Activity in Xenograft Models South San Francisco, CA, February 28, 2005 – Sunesis Pharmaceuticals, Inc. today presented positive results from in vivo studies of the company's Aurora kinase anti-cancer small molecule program at the Third International
01/10/05
Summary ToggleSunesis Announces Extension of Collaboration with Johnson & Johnson Pharmaceutical Research & Development South San Francisco, CA, January 10, 2005 – Sunesis Pharmaceuticals, Inc. announced today that it has extended its research collaboration with Johnson amp; Johnson Pharmaceutical Research amp; Development, L.L.C. (J&JPRD) through the end of 2005.